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Palavras-chave 
 
Carcinoma das células escamosas da laringe (CCEL), variação 
do número de cópias (CNVs), metilação de DNA, MLPA, MS-
MLPA, Array CGH. 
 
Resumo 
 
 
O carcinoma da laringe pertence a uma grande família de 
tumores conhecida como Cancro da Cabeça e do Pescoço que 
é considerado o sexto tipo de tumor mais maligno em todo o 
mundo. Dentro desta família, os tumores podem ter origem em 
diversos locais anatómicos, sendo a laringe o segundo órgão 
mais comummente afetado. O cancro da laringe apresenta uma 
incidência mundial de 1,9% e uma taxa de mortalidade elevada 
de 1,6%. Apesar dos avanços tecnológicos na área do 
diagnóstico e da terapêutica, a taxa de sobrevivência ao fim de 
5 anos não apresentou melhorias significativas. As baixas 
taxas de sobrevivências são explicadas essencialmente pelo 
diagnóstico tardio, pela agressividade do tumor e pela sua 
propensão a desenvolver metástases. Desta forma, torna-se 
essencial a identificação de biomarcadores com valor de 
diagnóstico e prognóstico a fim de detetar a presença do tumor 
numa fase mais precoce. Este estudo surge com o objetivo 
principal de caracterizar o perfil genético e epigenéticos do 
carcinoma das células escamosas da laringe com recurso às 
técnicas de MLPA, MS-MLPA e array CGH, usando oito 
amostras tumorais e sete amostras não-tumorais contra laterais 
ao tumor, ambas coletadas após cirurgia A análise genética 
revelou uma maior taxa de ganho de material genético nos 
cromossomas 3q, 8q, 11q, 14q13.1, Xp22.31, Xq21.1 e perda 
de material genético nos cromossomas 3p, 9p23.1 e Y. O 
ganho dos genes MYC e TNFRSF1A revelou ser o evento mais 
comum entre as amostras analisadas. Relativamente ao perfil 
epigenético, observou-se que os genes CDKN2A, CHFR, 
RARβ e RASSF1 se encontravam metilados nas amostras em 
estudo. Em suma, este trabalho permitiu identificar algumas 
alterações genéticas e epigenéticas descritas na literatura como 
estando associadas ao CCEL, assim como alterações 
associadas ao desenvolvimento tumoral. Foram ainda 
identificadas alterações que ainda não foram reportadas como 
estando associadas ao cancro. Desta forma, este estudo piloto 
permitiu dar início ao estudo de potenciais biomarcadores 
associados ao CCEL. Porém, novos estudos devem ser 
realizados, com um número de amostras superior, de forma a 
identificar alterações genéticas significativas no 
desenvolvimento e progressão do CCEL e associa-las às 
características clinico patológicas dos doentes. 
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Abstract 
 
Laryngeal carcinomas belong to a bigger family of tumours 
known as Head and Neck Cancer (HNC). HNC is the sixth 
most malignant type of cancer in the world and it can arise 
from several anatomical sites. Among them, the larynx is the 
second most common affect organ. The incidence of laryngeal 
carcinoma is 1,9% worldwide and it presents a high mortality 
rate (1,6%). Despite technological advances in diagnosis and 
treatment fields, the 5 year-survival rate did not improved 
significantly. The low survival rates are mainly explained by a 
late diagnosis, tumour aggressiveness and the fact that 
laryngeal carcinoma metastasize easily. Taking this into 
consideration, it is essential to identify biomarkers with 
significant diagnostic and prognostic value in order to 
anticipate the detection of laryngeal carcinoma in an early 
stage. This study arises mainly for characterize the genetic and 
epigenetic profile of laryngeal squamous cell carcinoma 
(LSCC). Eight LSCC samples and seven non-tumour samples 
contralateral to the primary tumour were collected upon 
resection surgery and characterized by MLPA, MS-MLPA and 
array CGH. The results showed that gain of genetic material 
was mainly present in chromosomes 3q, 8q, 11q, 14q13.1, 
Xp22.31 and Xq21.1 while genetic loss occurred mainly in 
chromosomes 3p, 9p23.1 and Y. Gain of MYC and TNFRSF1A 
was the most common event among the tumour samples 
included in this study. Regarding the methylation profile, the 
genes CDKN2A, CHFR, RARβ e RASSF1 were the only ones 
which were methylated in this samples. In conclusion, this 
study allowed to identify genetic alterations associated with 
LSCC that have already been reported in scientific papers as 
well as alterations that have been associated with tumour 
development and progression. In addition, a few genetic 
alterations which have never been reported as being associated 
with human cancer before were identified. Nevertheless, new 
studies must be carried out, with a higher number of samples. 
Ultimately, the main goal would be to identify genetic 
alterations significantly associated with LSCC progression and 
establish a correlation with clinicopathological data. 
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1 Introduction 
1.1 The Larynx 
The larynx is an organ located in the throat with approximately 5 centimetres wide. It 
is made by a rigid wall reinforced by hyaline cartilage and smaller elastic cartilages, all of 
which are connected by ligaments. Also, the surface of larynx is composed by stratified 
squamous epithelium and, at some points, this epithelium undergoes a transition to ciliated 
pseudostratified columnar epithelium. Underneath this epithelium there are several mucous 
and serous glands (1,2).  
 The larynx can be divided in three mains parts 
(Figure 1): 
I. Top: Supraglottis (the area above the 
vocal cords; contains the epiglottis 
cartilage); 
II. Middle: Glottis (where vocal cords are 
located); 
III. Bottom: Subglottis (the area below the 
vocal cords which is connected to 
trachea) (1,2). 
 
 The larynx is responsible for three physiological functions: 
I. Breathing: the larynx allow the passage of air, from pharynx to trachea;  
II. Speaking: through vibration of vocal cords;  
III. Swallowing: epiglottis prevents the entrance of food and liquid into lungs 
(1,2).  
1.2 Cancer 
A neoplasm can be defined as an abnormal mass in a specific tissue made by 
transformed cells which continue to replicate uncoordinated and excessively, even after the 
cessation of the initial stimuli that promoted the change. Genetic changes are associated to 
the origin of all neoplasms, causing unregulated proliferation independent of physiologic 
growth-regulatory stimuli (3). Furthermore, the cells undergo a set of changes involving not 
Figure 1 - Anatomy of Larynx. Adapted from: 
National Cancer Institute - U.S. Department 
of Health and Human Services   2014 (2) 
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only uncontrolled proliferation but also misregulated differentiation and loss of checkpoint 
control and accumulation of chromosomal aberrations and aneuploidies (4). 
Neoplasm can also be referred as a tumour and it can be divided into benign and 
malignant, based on its potential clinical behaviour (3): 
 Benign tumours usually remain localized and do not spread to other sites. Also, 
they are easily removed by local surgery and the patient generally survives 
 Malignant tumours, also known as cancers, are characterized by invasion and 
destruction of adjacent structures, metastasis, high risk of recurrence and death.  
Nevertheless, all tumours are composed by two basic components: (1) parenchyma, 
which is made by transformed cells (neoplastic cells) and determinates the biologic 
behaviour of tumours; (2) stroma, made by connective tissue, blood vessels and host-derived 
inflammatory cells, which is fundamental to support the growth of cells (3).  
1.2.1 Hallmarks of Cancer 
The hallmarks of cancer are a set of characteristics which are developed during the 
multistep development of tumours. They are involved in tumour growth and its spread to 
other sites (metastization), allowing us to understand the diversity of neoplastic diseases 
(5,6). 
According to Hanahan and 
Weinberg (2000), there are six hallmarks 
of cancer: sustaining proliferative 
signalling, evading growth suppressors, 
resisting cell death, inducing angiogenesis, 
activating invasion and metastasis and 
enabling replicative immortality. Genomic 
instability and inflammation underlie these 
hallmarks. In the last years, more 
hallmarks have been suggested: 
reprogramming of energy metabolism, 
evading immune destruction, tumour-
Figure 2 - The Hallmarks of Cancer. Adapted from Hanahan D 
and Weinberg RA 2011 (6) 
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promoting inflammation and genome instability and mutation (Figure 2) (5,6). 
1.3 Head and Neck Cancer and Laryngeal Carcinoma 
Laryngeal carcinoma is part of a bigger family of tumours known as Head and Neck 
Cancers. Besides larynx, this family of tumours can arise from nine more anatomic sites: 
nasal cavity/paranasal, oral cavity, salivary gland, trachea, thyroid, nasopharynx, 
oropharynx and hypopharynx. At least 90% of all histological head and neck cancers are 
represented by squamous cell carcinoma (SCC) and they generally arise from the oral cavity, 
oropharynx, larynx and hypopharynx. Therefore, the term head and neck squamous cell 
carcinoma is frequently used to refer this anatomical subsites (7–9). According to WHO 
(World Health Organization), SCC represents 95% of the malignancies that affect the larynx. 
In most cases, laryngeal cancer has origin on the vocal cords in the glottic region (50%-60%) 
or in supraglottic region (30%-40%) (10,11). 
1.4 Laryngeal Carcinoma 
1.4.1 Clinical features 
The signs and symptoms depend on the localization and the size of the tumour. The 
most common ones are voice changes/hoarseness which is considered to be an early 
symptom in glottis cancer. Symptoms of supraglottic and hypopharyngeal tumours may 
include not only voice changes but also dysphagia (trouble swallowing), lump/mass in the 
neck, haemoptysis (coughing of blood) and odynophagia (painful swallowing). Finally, in 
subglottic tumours symptoms such as dyspnoea (breathing discomfort/impaired breathing) 
and stridor (abnormal high-pitched sound produced by turbulent airflow through a partially 
obstructed airway) are common (2,10).  
1.4.2 TNM classification 
The TNM classification (Table 1 and 2) is an anatomically based system used 
worldwide for cancer staging. TNM classification is divided in three categories: (1) T: 
primary tumour site; (2) N: regional lymph node involvement; (3) M: presence/absence of 
metastases. Therefore it records the primary and regional nodal extent of the tumour as well 
as presence or absence of metastastic spread. 
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Table 1 - TNM Clinical Classification. Adapted from: Sobin et al. (2011) (12) 
T – Primary Tumour 
Tx: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
T1-T4: Carcinoma in situ. 
N – Regional Lymph Nodes 
Nx: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis in a single ipsilateral lymph node ≤ 3cm in dimension 
N2a: Metastasis in a single ipsilateral lymph node whose dimension ranges from 3 cm to 
6 cm 
N2b: Metastasis in multiple ipsilateral lymph nodes ≤ 6 cm in dimension 
N2c: Metastasis in bilateral or contralateral lymph nodes ≤ 6 cm in dimension 
N3: Metastasis in a lymph node > 6 cm in dimension 
M – Distant Metastasis 
M0: No distant metastasis 
M1: Distant metastasis. 
  
Table 2 - Stage Grouping was developed to condensate the three categories of TNM clinical classification. In the TNM 
system, carcinoma in situ is considered Stage 0, stages I and II are tumours localized in the organ of origin, tumours that 
spread to lymph nodes are in stage III while stage IV corresponding to tumour with distant metastasis. Adapted from: 
Sobin et al. (2011) (12) 
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 
T3 
N1 
N0 
M0 
IVA T4a, T4b 
T1,T2, T3 
N0, N1 
N2 
M0 
IVB T4b 
Any T 
Any N 
N3 
M0 
IVC Any T Any N M1 
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1.4.3 Epidemiology and Risk Factors 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
malignant tumour in the world and the laryngeal carcinoma is the second one within HNSCC 
(13). More specifically, according to GLOBOCAN 2012, the incidence of laryngeal 
carcinoma worldwide was 1.9% (138 102 new cases), more than 73 000 people died (1,6%) 
and the 5-year prevalence was about 2.5% (14,15).  
According to Portuguese Society of Otorhinolaryngology and Cervico-Facial 
Surgery (SPORL), Portugal is the third European country with the highest number of 
laryngeal carcinoma cases (16). 
It is known that laryngeal cancer risk is strongly linked to age and sex. Overall, the 
incidence of this carcinoma is higher in adult males, between 60 and 70 years old (10,17).  
Alcohol and tobacco are the two main risk factors of larynx cancer in developed 
countries, in the western world, and they account for the majority of cases.  Through 
epidemiological studies it was possible to identify an association between alcohol drinking 
with laryngeal cancer risk, as well as, a synergistic effect with tobacco smoking (10,17,18). 
Moreover, it is known that tobacco on its own is responsible for 85% - 90% of laryngeal 
squamous cell carcinoma (LCSS) (11).  
Other risk factors are the exposure to other compounds, such as metal dust, cement 
dust, varnish and lacquer, as well as ionizing radiation, diesel exhausts, sulphuric acid mists 
and mustard gas. Also, through epidemiological studies, it was possible to identify an 
Figure 3 - Laryngeal Carcinoma Incidence Worldwide in 2012. Source: GLOBOCAN 2012 (14) 
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association between cancer of the larynx and Human Papillomavirus (HPV) (10,17). Among 
all HPV subtypes detected in patients with cancer of the larynx, the prevalence of infection 
by HPV-16 and -18 seems to be much higher than the infection by other types (13). X. Li et 
al. (2013) showed a strong association between HPV-16 with laryngeal carcinoma (19). 
However, the findings regarding the frequency of HPV infection among laryngeal invasive 
lesions or carcinomas are quite heterogeneous (19,20). According to Torrente et al. (2011), 
the method of detection of HPV-16 may explain this heterogeneity. It appeared that those 
studies that used ELISA (enzyme-linked immunosorbent assay) were consistent with HPV 
being an important risk factor only for tonsillar carcinoma while those that used tumour-
based DNA amplification suggested that HPV were also a risk factor for oral, laryngeal and 
oropharyngeal cancer. Other factors that may influence are methodological differences, 
quality of the sample and sample size (21). Both techniques have different sensitivities and 
specificities that may explain the inconsistence between results. Also, some smaller studies 
might be under the influence of a selection bias explained either by the preferential inclusion 
of specific samples or by submission and publication of studies with high HPV prevalence. 
1.4.4 HPV-Induced Carcinogenesis 
HPV is an 8 kb circular double-stranded DNA non-enveloped virus which belongs 
to the family Papillomaviridae. However, there is only one strand of the genome which is 
transcribed into two different classes of proteins expressed by alternative splicing: early non-
structural regulatory proteins (E1-E7) and late structural proteins (L1 and L2) (22). HPV is 
an obligatory intranuclear virus which means that it must infect mitotically active cells in 
order to establish itself in epithelia. More than 200 different HPV genotypes have already 
been described and they can be classified as high-, intermediate or low-oncogenic risk 
according to their association with cervical cancer. By 1995, IARC (International Agency 
for Research on Cancer) had already recognized that high-risk HPV-16 and -18 were 
carcinogenic in humans. In HNSCC, HPV-16 is, by far, the most common genotype (90-
95%) (21). 
The infection by HPV can achieve basal and parabasal cells of epithelium through 
the site of mucosal injury, metaplastic epithelium or through squamocolumnar junction. In 
the larynx, HPV-induced proliferation results in a metaplastic alteration and formation of 
multi-layered squamous cell epithelium. In HPV-induced carcinogenesis (Figure 4), 
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integration of HPV DNA into the host cell genome is crucial. After integration, E1 or E2 
open reading frames are disrupted or deleted, leading to loss of gene expression and 
upregulation of viral oncoproteins E6 and E7 and consequently to DNA instability. More 
specifically, E6 binds and induces the degradation of p53 suppressor protein while E7 
protein binds to pRb (retinoblastoma protein) which leads to facilitation of DNA replication 
proteins expression. The molecular consequence of such expression is cell cycle entry and 
inhibition of p53-mediated apoptosis which will lead to virus replication and accumulation 
of DNA aberrations. Also, the oncogenic infection associated with E6 and E7 expression in 
basal layer, where stem cells are located, leads to disruption of cell cycle checkpoints. 
Additionally, E6 interferes with DNA repair enzymes and E7 induce chromosome 
abnormalities by the disruption of centrosome synthesis. Overall, the genetic instability 
induced by HPV may lead to emergence of tumorigenic cells. Alongside with molecular 
events there are morphologic alterations of epithelium which are represented by an increased 
mitotic rate, aneuploidies and increased rate of mutation in the host cell (21,23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.5 Non HPV-Carcinogenesis 
It has already been accepted that solid tumours, such as LSCC, result from a multistep 
process where genetic alteration are accumulated (24). Renan et al. (1993) suggested that 
LSCC develops by the accumulation of 6 to 10 independent genetic events (25,26). Through 
experimental studies, it was possible to demonstrate that the progression of the 
histopathological phenotype of LCSS correlates with genetic progression of HNSCC (24). 
Taking this into consideration, we now know that the evolution and progression of LSCC 
result from a multiple stepwise alterations that include not only genetic alterations but also 
Figure 4  - Deregulation of cell cycle by HPV. Adapted from Leemans et al. (2011) (23) 
CDKN2A 
CDKN1A 
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abnormalities in cellular and molecular pathways in the squamous epithelium. In HNSCC, 
it has been suggested a model of molecular progression from premalignant lesions to 
invasive carcinoma (27). However, since genetic alterations in laryngeal carcinomas are 
usually studied as part of head and neck cancers, there is not much information about 
molecular progression that allow a clear differentiation between laryngeal malignancies and 
the other cancers included in head and neck family. Also, it is not clear which genes 
participate in the different histopathological phases of LSCC. In Figure 5 is represented a 
few molecular alterations and its probable times of onset in cancer of the larynx (24,28–30).  
 
Furthermore since larynx plays a fundamental role in human speech and 
communication as well as breathing and swallowing, the optimal management of patients 
with laryngeal cancers is critical. Taking this into consideration, the study of molecular 
biology and tumourigenesis of laryngeal cancers seems to be mandatory in order to enhance 
our understanding of the evolution of this disease. The main challenge is to identify specific 
tumour biomarkers that will help to improve survival and preserve the function of larynx 
(30). 
Figure 5 - A grey scale in the corresponding bars represents the most probable times of onset of some molecular alterations 
in laryngeal carcinogenesis. (LOH - loss of heterozygosity). Adapted from: Almadori et al. (2004) (24) 
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1.4.6 Multistep Laryngeal Carcinogenesis: Genetic Model of Transformation and 
Neoplastic Progression. 
Although the overall genetic and molecular mechanisms of LSCC do not remain clear 
enough, Marcos et al. (2011), through the study of multigenic gains and losses by Multiple 
Ligation-dependent Probe Amplification (MLPA), proposed a genetic model of multistep 
laryngeal carcinogenesis (31). The results allowed the construction of an expanded model of 
transformation and neoplastic progression which include not only the classic sequence of 
steps (normal mucosa, precursor lesions, invasive tumour) but also normal mucosa tobacco 
and alcohol exposed, negative and positive lymph node primary tumour and lymph node 
metastases (Figure 6).  
1.4.7 Cytogenetic Alterations in Laryngeal Carcinoma 
Since laryngeal carcinoma develops through the accumulation of multiple genetic 
changes, its karyotypes are generally complex and have a non-random pattern of 
chromosomal alterations, including deletions and amplifications. In the cancer of larynx, the 
structural rearrangements are frequently located in the chromosomes 1 to 5, 7, 8, 11, 12 and 
15. 43% of the total breakpoints are located in pericentromeric regions, including 
centromeric bands p10 and q10 and juxtacentromeric bands p11 and q11. Also, the most 
common imbalances are partial or total loss of chromosome arms 3p, 5q, 8p, 9p, 13q, and 
17p and gain of chromosomal regions 3q, 5p, 7p, 8q, 11q13,17q and 18p (32,33). By 2007, 
17 recurrent structural alterations (translocations (t), isochromosomes (i) and deletions (del)) 
Figure 6 - Genetic progression model proposed by Marcos et al. (2011). [( ) smoker patients and also exposed to alcohol 
(-): genetic loss; (+): genetic gain; PL: precursor lesion; SCC: squamous cell carcinoma; SCCN+: SCC with positive lymph 
node; LNM: lymph node metastases;         : key genes between 2 steps] (31) 
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have already been identified, being i(8q), i(3q), i(5p) del(3)(p11) and gene amplification in 
11q13 the most common among them (33,34). Taking this into consideration, some of these 
chromosomal regions that are better characterized in LSCC and/or in HNSCC will be 
discussed individually in the following sections. 
1.4.7.1 Region 3p 
Partial/total loss of 3p is one of the most common genetic alteration in LCSS. In this 
region are located many tumour suppressor genes such as FHIT (fragile histidine triad), 
encoded on 3p14.2. This gene was detected in LCSS and precursor lesions. The decreased 
expression of FHIT, which may be caused by deletion or promoter methylation, was detected 
in about 42% of LCSS and 23% of dysplasia lesions (33). In a normal physiological state, 
FHIT [Uniprot: P49789] contributes to the regulation of the expression of genes which are 
important for cell proliferation and survival, such as CCND1 (cyclin D1). Also, FHIT has a 
role in the induction of apoptosis and functions as a tumour suppressor gene. Loss of FHIT 
protein may lead to abnormal cell proliferation probably by breakdown of G0/G1 arrest in the 
larynx and gain of apoptosis resistance during carcinogenesis (35).  
Other genes mapped on this region are RARβ (retinoic acid receptor, beta), CTNNβ1 
(catenin (cadherin-associated protein), beta 1, 88kDa) and MLH1 (mutL homolog 1). 
The RARβ gene (chromosome 3p24) encodes for a retinoic acid receptor beta which 
participates in the mediation of cellular signalling in embryonic morphogenesis, cell growth 
and differentiation through binding retinoic acid.  In HNSCC, loss of RARβ has been 
associated with cell immortalization and, in some patients, with resistance to growth 
inhibitory effects of retinoids. In laryngeal cancer specifically more studies have to be done 
in order to understand better the role of such loss in carcinogenesis (36,37).  
 β-catenin, encoded on 3p21, is part of wingless-Wnt signalling cascade which is 
involved in cellular proliferation and differentiation. Abnormal Wnt signalling has been 
associated with several human cancers. On the other hand, cytoplasmic β-catenin binds to 
the intracellular domain of E-cadherin in order to maintain cell adhesion. This protein is also 
downregulated in many human cancers, including in LCSS. Cadherin and catenin form a 
complex which is important not only in cell adhesion and differentiation but also in cell 
migration and tumour suppression. It seems that the loss of expression of catenin may be 
implicated in tumour invasion and metastasis in patients with supraglottic tumours. 
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However, more research is necessary to clear up the involvement of this protein in malignant 
transformation of laryngeal cells (38,39).  
MLH1 [Uniprot: P40692], mapped on chromosome 3p22.3, is a DNA mismatch 
repair (MMR) gene. As a briefly explanation, the MMR pathway targets DNA replication 
errors, such as base substitution mismatches as well as insertion-deletion mismatches, that 
escape the proofreading function of DNA polymerase. MLH1 has a role in DNA damage 
signalling and in meiosis (40). In LCSS, MLH1 is also downregulated (26,41). Moreover, 
Sasiadek et al. (2006) suggested the existence of an interaction between amplification of 
CCND1 and downregulation of MLH1 in LCSS (41). 
1.4.7.2 Region 3q 
Genetic gain in 3q region is frequent in SCC. Furthermore, it has been reported an 
overlapping area of gain at 3q26 in different anatomic sites, including the larynx. In this 
region is located the hTERC gene (human telomerase RNA component) which encodes the 
RNA component of human telomerase. This enzyme plays a role in cellular senescence by 
adding telomere repeat TTAGGG. Telomerase comprises a protein component with reverse 
transcriptase activity as well as an RNA component that acts as template for the telomere 
repeat (42). When this enzyme is overexpressed, cells with critically short telomeres avoid 
apoptosis and amplification of hTERC has been seen in many tumour sample and 
immortalized cell lines which suggest that its transcription may be upregulated during 
tumourigenesis. Liu et al. (2012) found this alteration in LCSS patients with moderate 
dysplasia, severe dysplasia, carcinoma in situ and invasive carcinoma. They saw that 
amplification of hTERC was present at low frequency in normal epithelium and mild 
dysplasia when compared with the stages mentioned above, which may suggest that the 
amplification may be implied in the progression to invasive LCSS (42,43).  
Gains in 3q region are commonly associated with isochromosome formation (an 
abnormal chromosome with two identical arms, either two short or two long arms, normally 
resulting from a transversal division through the centromere at meiosis II) and is usually 
accompanied by the loss of 3p mention above (33,44).  
1.4.7.3 Region 7p 
One of the major alterations on this region is the overexpression of EFGR (epidermal 
growth factor receptor) gene, which is mapped in 7p12. EGFR codes for a transmembrane 
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receptor tyrosine kinase which has a major role in the regulation of cancer cells proliferation 
as well as cell cycle progression (33,45). EGFR [Uniprot: P00533] is able to activate several 
downstream signalling cascades, including the RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, 
PLCγ-PKC and NF-kappa-B, that regulate numerous cellular processes. LCSS patients with 
a high expression of EGFR tend to have a poorer prognosis (45). Braut et al. (2009) 
suggested an association between the increase of EGFR expression and gene amplification 
with the increase of biological aggressiveness of glottic lesions. They also conclude that 
gene amplification is an early event in glottic cancer (46).  
1.4.7.4 Region 8q 
In LSCC, partial or entire gain of 8q by the formation of isochromosome or 
unbalanced structural rearrangements is common. Within the genes mapped in this region, 
MYC (v-myc avian myelocytomatosis viral oncogene homolog) is probably the alteration 
more studied (33). MYC is mapped on 8q24.21 and codes for a transcription factor which 
has a role in activation and repression of transcription. Moreover, MYC is implicated in 
control of cell proliferation by upregulating cyclins and downregulating CDKN1A, 
differentiation and programmed cell death (47,48). In LSCC, amplification and 
overexpression of MYC happen frequently (30-68%) (33). MYC may be activated by gain or 
amplification in laryngeal carcinogenesis. Liu et al. (2013) found a strong association 
between MYC amplification and histopathological stages which suggests that this alteration 
may be implied in the development of LSCC (47). Furthermore, amplification of MYC gene 
is considered an early event during the progression of laryngeal dysplasia (47). On the other 
hand, Coskunpinar et al. (2014) observed a decreased expression of MYC in metastatic 
tumours. MYC suppresses transcription of integrins, which have an important role in 
metastasis of cancer of the larynx and their silencing appears to result in inhibition of 
metastasis. Taking this in consideration, it is easy to understand the loss of expression of 
MYC in a metastatic phenotype (48). 
1.4.7.5 Region 9p 
In this regions is located CDKN2A (cyclin-dependent kinase inhibitor 2A) which is 
encoded on chromosomal region 9p21 (33). CDKN2A inhibits catalytic activity of 
CDK/cyclin D1 complexes through the bind to CDK4 (cyclin dependent kinase 4) and CDK6 
thus. This complex is needed for RB1 protein phosphorylation as well as cell cycle 
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progression through G1/S restriction point (29,49). The loss of expression of CDKN2A has 
been detected in 52-82% of HNSCC, including LSCC. There three known mechanism that 
lead to gene inactivation in human cancers: homozygous deletions, point mutations and 
promoter hypermethylation. Additionally, LOH is also found in these tumours. The 
deregulation of cell cycle leads to genomic instability, resulting in cancer development. Also, 
downregulation of CDKN2A is associated with poor survival in patients with LCSS 
(29,33,49).  
1.4.7.6 Chromosomal band 11q13 
11q13 rearrangements have been extensively studied in cancer and its pathogenic 
importance is supported by several studies. Amplification of this region is commonly found 
in human cancer and, within these tumours, HNSCC seems to be the one that has a higher 
rate of amplification (36%) (50). Also, 11q13 amplification is associated with lymph node 
metastasis and decreased disease-free survival as well as overall survival (50).  
The numerical and structural anomalies in 11q13 region may result by the formation 
of intra–chromosomal repeats that are cytogenetically visible as homogenously stained 
region (hsr) or by the presence of extra copies of chromosome 11 (51). Shuster et al. (2000) 
suggested that 11q13 amplification is most probable arised through breakage–fusion–bridge 
(BFB) cycles (51,52) in which the breakage of a chromosome leads to loss of telomeric end. 
After that, the broken end of this chromosome fuse with the newly synthesized strand, 
resulting in the formation of dicentric chromosome that forms a bridge during anaphase. 
Next, the mechanical tension applied in the centromeres by the mitotic spindles will lead to 
asymmetrical chromosomal break. Finally, the resulting daughter cells will contain a 
chromatid with an inverted repeat at the fragmented end or a chromatid with loss of the 
repeated segment. Unless the broken end is capped, the next BFB cycles will result in 
augment of the repeated segment (Figure 7) (53).  
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In 11q13 region are located several oncogenes, including CCND1 and CTTN 
(cortactin). The amplification and upregulation of the oncogene CCND1 is one of most 
studied alterations and it has been associated with laryngeal cancer due to alterations of cell 
cycle regulation. Other genes in this region, such as FADD (Fas associated protein with dead 
domain) and ORAOV1 (oral cancer overexpressed 1) have been studied in the last years 
(33,51). 
CCND1: Most studies focused on CCND1 and its involvement in laryngeal cancer 
progression. It has been proved that CCND1 is associated with carcinogenesis (Jin and Jin, 
2007). Cyclin D1 [Uniprot: P24385] has an important role in cell cycle progression from G1 
to S-phase through directly binding to CDK4 and CDK6. Overexpression of this gene allow 
cell growth in the absence of growth signals which is essential for cancer development 
(54,55). Since overexpression of cyclin D1 has been found in pre-malignant lesions, it is 
thought that this is an early event in tumourigenesis which is associated with a poor 
prognosis(33,55). According to Almadori et al. (2004) cyclin D1 overexpression always 
anticipates gene amplification which is thought to be a more stable and non-reversible 
alteration in tumour cells (24).  
CTTN: this gene [Uniprot: Q14247] is involved in the organization of actin 
cytoskeletal and cell structure. In addition, cortactin has a role in the regulation of cell 
migration. Its aberrant regulation contributes to tumour cell invasion and metastasis. 
Figure 7 - The mechanism of breakage–fusion–bridge (BFB) cycles. Adapted from: Ciullo M et al. 2002 (53) 
Broken chromosome 
regains a telomeric cap 
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Cortactin is involved in cancer cells growth as well as in tumour progression, possibly by 
impairing of EGFR downregulation (56,57). It has been seen that overexpression of CTTN 
results in a bigger invasive potential (58). Amplification of CTTN is also associated with a 
poor prognosis in HNSCC because expression of cortactin has been shown to correlate with 
lymph node metastasis (59).  
FADD: FADD [Uniprot: Q13158] mediates FAS-induced apoptosis. FADD is an 
apoptotic adaptor molecule that is able to recruit caspase-8 or 10 to activate receptors (Fas 
or TNFRSF1A) in order to form an aggregate known as death-inducing signalling complex 
(DISC) which will induce caspase-8 activation. This event will lead to initiation of subsquent 
cascade of caspases mediating apoptosis. Its overexpression in laryngeal carcinoma seems 
to affect cell cycle regulation (50,60). 
ORAOV1: this gene has probably a role in the development and/or progression of 
human cancers and it is associated with a bad prognosis and low survival rates. Although 
ORAOV1 is amplified in laryngeal carcinoma, its role on laryngeal carcinogenesis is still 
unknown and more studies need to be carried out (51).  
1.4.7.7 Region 13q 
Stembalska et al. (2006) identified two critical chromosomal regions as probable 
targets of deletion by CGH analysis: 13(q21-q32) and 13q34. Within this regions, LOH 
analysis revealed three different regions of deletions: 13(q21.1-q22.1), 13(q31.1-q32.3) and 
13q34. Additionally, they observed a high frequency of LOH in 13q14 which comprises RB1 
(retinoblastoma 1) gene [Uniprot: P06400], a key regulator of entry into cell division and a 
tumour suppressor gene (61). Although allelic loss of RB1 gene is frequent in LSCC, the 
role of its inactivation is still unclear in this type of cancer (33). A few tumour suppressor 
genes and some genes implied in carcinogenesis are mapped in these regions. For example, 
BRCA2 (breast cancer 2, early onset), mapped on 13q21 has already been associated with 
several types of human cancers and it predisposes to various types of cancer, including 
laryngeal carcinoma (61,62). Also, mutations in ING1 (inhibitor of growth family, member 
1), mapped on 13q34, have already been found in HNSCC. This particular gene is involved 
in control of cell cycle and apoptosis. In LCSS, Stembalska et al. (2006) identified three 
possible important genes within 13q31.1-q32.3 region: GPC5 (glypican 5), GPC6 (glypican 
6) and CLDN10 (claudin 10). The first two are involved in control of cell proliferation and 
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the last one codes for an integral membrane protein and a component of tight junction strands 
(61).  
1.4.7.8 Region 17p 
Alterations in the tumour suppressor gene TP53 (17p13) are also extensively study 
in LSCC, suggesting that mutations may be an early event in the neoplastic transformation. 
TP53 is often inactivated at the time of transition from pre-invasive to invasive carcinoma. 
Expression and accumulation of p53 is favoured in response to many stressful stimulus, 
resulting mainly in activation of genes that are responsible for DNA repair, cell cycle arrest 
and apoptosis. Patients with mutation in TP53 have poor prognosis whit shorter survival or 
a poor response to treatment (29,33). 
Todorova et al. (2014) detected this mutation in 43.5% of LSCC patients. However, 
they demonstrated that alterations in TP53 gene increased with the advancing of tumour, 
suggesting that this event probably occurs in later stages of LSCC (29). 
1.4.8 Epigenetic Alterations 
Epigenetic alterations can be defined as changes in gene function that cause a stably 
heritable phenotype without modifying the DNA sequence which means that these 
alterations are not encoded in the genome (4,63). The three main systems that are involved 
are DNA methylation, histone modification and RNA-associated silencing. Epigenetic 
changes are essential for physiological processes such as differentiation, silencing of 
chromosomal domains, stem cell plasticity, aging and genomic imprinting (4). However they 
are also associated with pathophysiological conditions, including the carcinogenesis process. 
The disruption of any system may result in an abnormal activation or silencing genes which 
may lead to the development of cancer (4,13,63). 
1.4.8.1 DNA methylation 
Within the epigenetic modifications, DNA methylation is still the one that is best-
studied in mammals. DNA methylation is defined as the addition of methyl groups (CH3) to 
the cytosine at carbon 5 position in DNA, resulting in the formation of 5- methylcytosine. It 
contributes to normal cell development, silencing of elements that are repeated through the 
genome, regulation of tissue-specific gene expression and imprinted alleles. DNA 
methylation has extensive effects on cellular growth and genomic stability. In mammalian 
cells, the most studied modification occurs at CpG nucleotides, where the cytosine is 
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methylated within this dinucleotide. There are about 28 million CpG sites in the genome, 
but in spite of being distributed across the human genome, CpG nucleotides are located 
mainly in regions with large repetitive sequences, such as centromeric repeats and in gene 
regulatory regions in short CpG-rich DNA stretches known as CpG islands. This CpG 
islands are mainly located at 5’end that occupy approximately 60% of the gene promoters in 
human cells (4,64).  
DNA methylation is catalysed by mammalian enzymes - DNA methyltransferases – 
that can be classified in: (1) de novo DNA methylatransferases (DNMT3A and DNMT3B) 
and (2) maintaining DNA methylatransferases (DNMT1). DNMT3A and DNMT3B target 
unmethylated CpGs and its activity is independent of replication while DNMT1 is activated 
during DNA replication and finishes the methylation process of a partially methylated DNA 
present in the cell after its division. Regardless the type of enzyme, the result of its activity 
will be the generation and maintenance of DNA methylation patterns that are hereditary. In 
tumours, although these enzymes appear to be overexpressed, so far only DNMT3B and 
DNMT1 were implicated in cancer development (4,65). 
The methylation of CpG nucleotides contribute to oncogenesis (Figure 8) mainly 
through hypomethylation of cancer genome, hypermethylation of the promoters of tumour 
suppressor genes and through direct mutagenesis. Additionally, DNA methylation promotes 
the binding of chemical carcinogens to DNA and increases the rate of Ultraviolet-induced 
mutations. 
 
1.4.8.1.1 DNA hypomethylation 
DNA hypomethylation or, in other words, loss of DNA methylation, was the first 
epigenetic alteration identified in cancer cells. CpG-poor regions undergo hypomethylation 
during cell transformation, following by a global decrease in total genomic 5- 
methylcytosine in cancer cells. DNA hypomethylation occurs in many genomic sequences, 
Figure 8 - DNA methylation in cancer cells. (Black circle - methylated CpG; White circle - unmethylated CpG.). CpG 
islands hypermethylated, resulting in gene silencing and concomitant hypomethylation of CpG-poor oncogene promoters 
leads to genomic instability and abnormal gene expression. Adapted from: Stirzaker C  et al 2014 (64) 
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such as repetitive elements, retrotransposons (reverse transcriptase genes that can move in 
the genome by reverse transcription of an RNA transposition intermediate), CpG poor 
promoters, introns and gene deserts (regions without protein-coding sequences neither 
obvious biological function) (4,64,66). 
According to Iliopoulos et al. (2011), three mechanisms have been proposed to 
understand the role of DNA hypomethylation in tumourigenesis (4): 
 Undermethylated DNA can lead to genomic instability, favouring mitotic 
recombination, deletions and translocations as well as chromosomal rearrangements. 
Also, hypomethylation of retrotransposons may result in their activation and 
translocation to other regions, leading to further disruption of the genome; 
 DNA hypomethylation may lead to activation and expression of proto-oncogenes 
which otherwise would be inactivated by methylation of CpG islands in the promoter 
regions. Some of the genes that are affected are oncogenes such as RAS and S100A4. 
 Loss of methylation may lead to disruption of genomic imprinting too. This happens 
in colorectal neoplasia in which loss of imprinting of IGF2 (insulin-like growth factor 
2) leads to an increased risk of develop this malignancy. 
1.4.8.1.2 Hypermethylation of the gene promoters  
 In normal human cells, CpG islands in tumour suppressor gene promoters are usually 
non-methylated. Rather, tumour cells are characterized by hypermethylation of promoters 
where CpG islands are found. This alteration is responsible for the silencing of tumour 
suppressor genes. Furthermore, hypermethylation of CpG islands can also inactivate other 
genes through the silence of transcription factors and DNA repair genes, leading to 
transformation of cells into a neoplastic phenotype. Hypermethylation of gene promoters 
leads ultimately to the formation of silent chromatin structure and aberrant silencing. The 
mechanism by which gene promoters are targeted for CpG hypermethylation is still unclear 
(4).  
1.4.8.2 DNA methylation in Larynx Carcinoma 
There is little information about epigenetic alterations involved in LSCC 
carcinogenesis. The epigenetic characteristic more studied is hypermethylation of some 
genes promoters. However this information and the conclusions drawn from the studies are 
sometimes conflicting. For example, some studies may state that these particular alterations 
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are connected with a set of clinic-pathological features while others do not find the same 
correlation. And this may be explained by the different methodologies, the stage of tumour 
samples as well as the site where the sample was removed. Also, intra and inter-assay 
variability has been considered relevant in methylation analysis studies (67,68). Some genes 
which have been described as having changes of the pattern of methylation during LSCC 
carcinogenesis are represented in Table 3.  
 
Table 3 - Genes with altered methylation pattern in laryngeal cancer 
Gene Gene name 
Locatio
n 
Function 
Level of 
methylation* 
References 
APC 
Adenomatous 
Polyposis Coli 
5q21-
q22 
Tumour 
Suppression 
(+) (30,67) 
CDH1 
Cadherin 1, 
type 1, E-
cadherin 
(epithelial) 
16p22.1 Cell adhesion (+) (13,38,69) 
CDH13 Cadherin 13 16q23.3 Cell adhesion (+) (30) 
CDKN2A 
(p16) 
Cyclin-
Dependent 
Kinase 
Inhibitor 2A 
9p21.3 
Tumour 
Suppression 
(+) (13,68,70,71) 
CDKN2B 
Cyclin-
Dependent 
Kinase 
Inhibitor 2B 
(p15, inhibits 
CDK4) 
9p21 
Tumour 
Suppression 
(+) (30,67) 
CHD5 
Chromodomain
-Helicase-DNA 
Binding Protein 
5 
1p36.3 
Tumour 
Suppressor 
(+) (13,72) 
CHFR 
Checkpoint 
with Forkhead 
and Ring finger 
domains, E3 
ubiquitin 
protein ligase 
12q24.3
3 
Mitotic 
Checkpoint 
(+) (30,67) 
DAPK 
Death-
Associated 
Protein Kinase 
1 
9q34.1 Apoptosis (+) 
(13,67,68,73–
75) 
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ESR1 
Estrogen 
Receptor 1 
6q24-
q27 
Hormone and 
DNA binding, 
activation of 
transcription; 
Metastasis-
suppressor 
properties 
(+) (30) 
FHIT 
Fragile 
Histidine Triad 
3p14.2 
Tumour 
Suppressor 
(+) (73) 
GSTP1 
Glutathione S-
Transferase Pi 
1 
11q13.2 
Protection 
against DNA 
damage 
caused by 
glutathione 
(+) (30,73) 
MGMT 
O-6-
methylguanine-
DNA 
methyltransfera
se 
10q26 DNA Repair (+) (68,71,73,75) 
MLH1 
mutL homolog 
1 
3p21.3 DNA repair (+) (26,68) 
RARβ 
Retinoic Acid 
Receptor, beta 
3p24 
Tumour 
Suppression 
(+) (30,67,73) 
RASSF1 
Ras association 
(RalGDS/AF-6) 
domain family 
member 1A 
3p21.3 
Tumour 
Suppression 
(+) (73,75) 
S100A4 
S100 calcium 
binding protein 
A4 
1q21.3 Oncogene (-) (13,76) 
TP73 
Tumour Protein 
p73 
1p36.3 
Pro-apoptotic 
and anti-
apoptotic 
properties 
(+) (30) 
* (+) – Hypermethylated ; (-) – Hypomethylated  
 
Chromodomain-Helicase-DNA Binding Protein 5 (CHD5): Loss of CHD5 has been 
observed in laryngeal carcinoma. CHD5 [Uniprot: Q8TDI0] is a tumour suppressor gene 
characterized by a chromodomain, a helicase ATP-binding domain and a functional domain. 
It is located in the nucleus associated with heterochromatin. CHD5 is involved in cell 
proliferation and differentiation through modification of chromatin. CDKN2A is a potential 
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downstream activated gene that regulates the p53/TP53 pathway which prevents cell 
proliferation (13). Loss of heterozygosity and instability of 1p36 was detected in laryngeal 
carcinomas. A study made by Wang et al. (2011) shown a decreased CHD5 mRNA and 
protein expression levels in LSCC when compared to clear surgical margin tissues. They 
also observed that downregulation of CHD5 was significantly associated with advanced 
stages of LCSS. This study allow them to conclude that decreased CHD5 expression may 
contribute to invasion and aggression of LCSS through the decreased apoptosis, increased 
proliferation and invasiveness. Furthermore, hypermethylation of the gene promoter was 
identified in Hep-2 cell line as well as in 60% of the LSCC samples (13,72). 
E-cadherin (CDH1): E-cadherin is a calcium dependent cell adhesion glycoprotein 
encoded by CDH1 gene located in the chromosome 16q22.1. This transmembrane 
glycoprotein has a highly conserved cytoplasmic tail which interacts with the cytoskeleton. 
It is involved in adhesion of epithelial cells as well as cell attachment, cell polarity and tissue 
architecture. E-cadherin is a key component of adherens junctions between epithelial cells. 
It is thought that its loss of function may contribute to progression of cancer through the 
increase of cell proliferation, invasion and/or metastasis (13,77). Rodrigo et al. (2002) 
demonstrated that E-cadherin is abnormally expressed in supraglottic squamous cell 
carcinomas and suggested that a decreased CHD1 expression may be a predictor of lymph 
node metastases (77,78). Also, in LSCC it has already been seen a correlation between 
reduced E-cadherin expression and decreased survival rates as well as vascular invasion. 
Some of the reasons that may explain these observations are CDH1 mutation, loss of 
heterozygosity or promoter hypermethylation. On the other hand, loss of E-cadherin was 
also associated with activation of epidermal growth factor receptor (EGFR) pathways which 
will promote cell proliferation. Moreover, in head and neck cancers, loss of E-cadherin is 
frequently found associated with promoter hypermethylation. Although epigenetic silencing 
is considered to be one of the main mechanisms of E-cadherin loss, more research is 
necessary to be done in order to identify more specific epigenetic changes in laryngeal SCC 
patients (13,38). 
Starska et al. (2013) accessed the CDH1 expression levels as well as the DNA 
methylation status of this gene and the results showed a high positive expression of mRNA 
and protein nuclear fraction of E-cadherin in laryngeal carcinoma tissues with lower 
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aggressive behaviour (tumour front grading1: 6-13) On the other hand, more invasive and 
aggressive laryngeal tumours (pTNM2  classification pT3 – pT4) demonstrated a higher 
frequency of CDH1 methylation status in the tumour samples. This findings suggest that e-
cadherin promoter is under epigenetic control and that CDH1 promotor methylation is 
connected with an aggressive, invasive and metastatic phenotype (69). 
Cyclin-dependent kinase inhibitor 2A (CDKN2A): CDKN2A is a key regulator of 
cell cycle that is methylated in HNSCC (68). Pierini et al. (2014) accessed methylation status 
of CDKN2A in 100 laryngeal carcinoma samples and obtained a frequency of 47.4%. They 
also establish an association between CDKN2A promoter methylation and increased tobacco 
carcinogen exposure which leads to gene inactivation, accumulation of genetic abnormalities 
and finally to cancer development. Also, a significant correlation was attributed to promoter 
hypermethylation and invasion of regional lymph nodes by cancer cells, suggesting that this 
event play a role in tumour cell migration (68).  
Death-Associated Protein Kinase 1 (DAPK1): DAPK1 codes for a 
calcium/calmodulin dependent serine/threonine kinase which is mapped in chromosome 
9q21.33. It is a tumour suppressor gene involved in many cellular signalling pathways that 
control cell survival, apoptosis and autophagy (13). In previous studies, the methylation of 
DAPK1 was proven to be a frequent event in laryngeal carcinoma (13,73,74). The loss of 
DAPK1 expression may be implied in loss of growth control and acquirement of apoptosis 
resistance (73). In LCSS, López et al. (2014) observed an association between the absence 
of methylated DAPK1 and advanced-stage tumours. It is known that the methylation of 
promoter region plays a major part in controlling DAPK1 transcription in LCSS (13,67). 
O-6-methylguanine-DNA methyltransferase (MGMT): MGMT [Uniprot: P16455], 
mapped in 10q26.3, encodes the enzyme O-6-methylguanine-DNA methyltransferase, 
which is involved in DNA repair through defence against the effects of O6-methylguanine . 
The enzyme is irreversibly inactivated after repairing alkylated guanine in DNA by 
transferring the alky group at the O-6 position to cysteine residue in the enzyme. 
                                                          
1  Sum of 6 parameters (cytoplasmic differentiation, nuclear polymorphism, number of mitosis, mode of 
infiltration, depth of invasion and plasmalymphocytic infiltration) which were graded from 1 to 4. The 
maximum score was 24 points and the group studied was divided into 3 subgroups (6-13, 14-21 and ≥ 22 
points). 
2 TNM classification of 2003 for head and neck carcinomas applied for classification of primary tumours (pT).  
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Hypermethylation of MGMT has been associated with cases where there are lymph node 
involvement. Pierini et al. (2014), through the methylation analysis of tumour tissues from 
100 patients with LSCC, obtained a percentage of MGMT methylation of 60,8% while 
Paluszczak et al. (2011) obtained a frequency of 54% after analyse 41 cases of LSCC (68,73). 
The loss of expression may be implied in increased mutation rate due to impairment of DNA 
repair mechanism induced by cigarette smoke nitrosamines. Once the DNA is damaged, the 
acquirement of a bigger migration potential as well as enhanced invasiveness is easier 
(68,71,73). 
Retinoic Acid Receptor, beta (RARβ): In HNSCC, loss of RARβ expression has been 
associated with increased keratinizing squamous differentiation in abnormal cells (67). 
Recently, Paluszczak et al. (2011) showed that, in laryngeal cancer, that lack of 
hypermethylation of RARβ is linked to a late-stage disease where lymph nodes are already 
involved. Also, methylated RARβ seems to facilitate the acquirement of uncontrolled 
proliferation and apoptosis inhibition (73). On the other hand Fernando López et al. (2014) 
observed that hypermethylation of RARβ was more frequent in LSCC samples which were 
poorly differentiated with little evidence of keratinization, suggesting that hypermethylation 
of the gene promoter is an early event of LSCC (67). 
Checkpoint with Forkhead and Ring finger domains, E3 ubiquitin protein ligase 
(CHFR): CHFR [Uniprot: Q96EP1] is mapped on chromosome 12q24.33 and codes for an 
E3 ubiquitin protein ligase. This enzyme is involved in mitotic checkpoints by delaying 
chromosome condensation in response to mitotic stress caused by microtubule poisons. In 
HNSCC, promoter hypermethylation of CHFR has been found in up to 30% of the cases. 
López et al. (2014) accessed methylation status of CHFR in 53 LSCC samples and 11% of 
them were aberrantly methylated. Moreover, the samples that had the CHFR methylated 
belonged mainly to a stage IV group of samples, suggesting that aberrant methylation of 
CHFR could emerge as a predictor of late stage LCSS (67). Stephen et al. (2010) also found 
CHFR methylation as one of the most frequently methylated genes (12 of 79 LSCC samples). 
However this event did not come up as a an independent predictor of late stage LCSS (30). 
mutL homolog 1 (MLH1): MLH1 is a DNA mismatch repair gene which is 
frequently found methylated in dysplasic lesions of HNSCC (30). Sasiadek et al. (2004) 
concluded that LOH and methylation were the most important silencing mechanisms of 
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MLH1 in laryngeal cancer (26). Furthermore, Pierini et al. (2014) found MLH1 
hypermethylation frequency of 46.4% (45 of 100 LSCC samples) and a positive association 
with lymph node metastases (68).  
S100 calcium binding protein A4 (S100A4): S100A4 encodes a protein that belong 
to the S100 family of proteins. They are localized in the cytoplasm and/or nucleus and they 
have been associated with several physiological functions such as regulation of cell cycle 
progression and differentiation, tubulin polymerization, motility and invasion. S100 genes 
comprise at least 13 members which are encoded on chromosome 1q21. S100A4 protein is 
able to promote angiogenesis, to induce degradation of extracellular matrix and to interact 
with cytoskeletal proteins which are involved in cell motility (79).  
 In LSCC, Liu et al. (2010) reported a higher expression in metastatic lymph nodes 
when compared to LSCC tissue and adjacent normal mucosa, suggesting that S100A4 may 
has a role in metastasis of LSCC. The mechanism responsible for regulation of S100A4 
expression is not clear yet. However, this study also suggested that S100A4 is regulated by 
DNA methylation. Therefore, hypomethylation seems to lead to high levels of S100A4 
expression which are associated with metastatic progression in LSCC (79). In tumour 
development and progression, S100A protein seems to be involved in not only in cell 
motility, invasion and migration but also in cell apoptosis, cell growth and differentiation. 
(76). 
1.4.9 Changes in Signalling Pathways 
In the past few years there have been many studies focused on tumour biology, 
including several subcellular pathways that have potential roles in tumour progression. 
Although there are evidences that demonstrate the essential role of signalling pathways in 
development and progression of head and neck cancers, the studies concerning alterations in 
these pathways on LSCC are little and further studies are needed to understand better the 
biology of LSCC individually (80,81). Some of these studies are going to be mentioned in 
the next sections.  
1.4.9.1 NOTCH signalling pathway 
Notch signalling pathway initiates when occurs an interaction receptor-ligand 
between two neighbouring cells, leading to proteolytic cleavages that release the cytoplasmic 
portion of Notch (IC) from de membrane. After Notch-IC enters into the nucleus, it binds to 
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a transcription factor known as CSL. Next, co-activators are recruited as well as histone 
acetyltransferases, leading to activation of CSL. In the absence of Notch signalling, CSL 
acts as transcriptional repressor by its binding to the promoters of its target genes and also 
the recruitment of co-repressors and histone deacetylases (82).  
The Notch signalling pathway is implied in many cellular processes, including the 
maintenance of stem cells, cell fate, proliferation and differentiation of epithelial cells and 
apoptosis (82). 
In 2009, Jiao et al. suggested for the first time a potential association between the 
role of NOTCH1 signalling pathway and LSCC progression by using laryngeal squamous 
cell carcinoma cell line Hep-2. Notch1 is one of the multifunctional transmembrane Notch 
receptors that have important roles in cellular differentiation and carcinogenesis. After 
activation of this receptor, it will be translocated to the nucleus and it will transactivates 
many target genes. Jiao et al. (2009) demonstrated that activation of Notch1 signalling 
pathway inhibits cell proliferation and is capable of cell cycle arresting in G0 to G1 phases 
as well as inducing apoptosis and reducing migration ability. These functions were coupled 
with alterations of numerous genes such as: (1) downregulation of cyclin D1 and CDK2 and 
upregulation of p53 important for cell cycle arrest; (2) overexpression of caspase-9 and 
caspase-3 which have a role in apoptosis and (3) downregulation of matrix 
metalloproteinases 2 and 9 which are important for loss of the ability of cell migration (80). 
1.4.9.2 EGFR-mTor signalling pathway 
One of the most studied alterations in carcinogenesis is the overexpression of the 
transmembrane tyrosine kinase EGFR which seems to be implied in cell transformation. The 
AKT/mTOR axis is one of the downstream pathways regulated by EGFR and belongs also 
to the 3-kinase (PI3K)-AKT pathway which has been implied in multiple cell functions such 
as proliferation, metabolism, autophagy, migration and apoptosis, being aberrantly activated 
in transformed cells (81,83). Lui et al. (2013) observed that, within HNSCC group, the 
prevalence of PI3K pathway mutations was higher in laryngeal tumours (84). AKT and 
mTOR proteins modulate cell cycle. Additionally, the latest represents a point where other 
cellular signalling pathways converge and so it is involved in apoptosis, cell survival, cell 
transformations, invasion, metastasis and angiogenesis in many human cancers (81). 
 LSCC patients in which mTOR is highly expressed seem to have a significant shorter 
disease free survival. Lionello et al (2014) found a direct and strong association between 
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EGFR and mTOR expression in LSCC cells. Their results also suggest that mTOR pathway 
might be involved in neo-angiogenesis in LSCC (81). Dionysopoulos et al. (2013) found 
also a strong interdependent relationship between mTOR and CCND1 expression and 
observed that patients with both molecules expressed had higher risk for shorter disease free 
survival than patients with high expression of only one (45). 
1.4.9.3 JAK-STAT pathway 
STAT (Signal transducers and activators of transcription) proteins are cytoplasmic 
transcription factors that transduce signals from cytokines and growth factors to the nucleus. 
Also they regulate the expression of several target genes (85). The JAK-STAT pathway is 
widely implicated in normal cellular functions such as proliferation and differentiation, 
angiogenesis, innate and adaptive immunity and apopotisis. The abnormal activation of this 
pathway contributes to formation and progression of human cancers. Overall, constitutively 
activated JAK-STAT signalling pathway have been implicated not only in the progression 
but also in prognosis of cancer and its resistance to conventional treatment (86).  
One of the members of STAT family, STAT3, has been considered to be an oncogene 
which have a key role in promoting proliferation, differentiation and cell cycle progression. 
Some studies had shown that inhibition of STAT3 activity in human cancer cells induces 
apoptosis and/or cell cycle arrest, abrogation of transforming growth factor and suppression 
of oncogenic cell growth (87). Gao et al. (2005), by inhibiting STAT3 expression with a 
siRNA, demonstrated that downregulation of STAT3 leaded to growth suppression and to 
induction of apoptosis in Hep2 LCSS cell line (87). Also, through the usage of a selective 
JAK-2 inhibitor, Zhang et al. (2010) suggested that down-regulation of STAT3 is associated 
with decreased proliferation and increased apoptosis in the same cell line (85). 
1.5 Cytogenetic and Cytogenomic Lab Techniques and Cancer Genetics 
1.5.1 Array CGH (comparative genomic hybridization) 
The array CGH is a technique that allows the screening of the complete genome with 
the purpose of detecting genomic imbalances, namely copy number variations (CNVs). This 
technique is based on CGH, a competitive hybridization reaction in which the genome of a 
test sample or control compete for binding to a preparation of normal metaphase 
chromosomes (88). The array CGH (aCGH) combines the CGH and microarray techniques. 
The difference lies in the fact that it is used a solid support, usually a glass microscope slide, 
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with small cloned or synthesized DNA fragments (oligonucleotides with about 200kb in 
size) instead of using metaphase chromosomes. These oligonucleotides represent target areas 
of the genome and that alone increases the resolution of traditional CGH technique that 
allowed only the detection of chromosome aberration between 5 and 10 Mb. Each 
microarray chip contains up to 180 000 oligonucleotides (89–92). 
The underlying mechanism of aCGH is based on the following steps: extraction of 
DNA sample and controls, marking them with different fluorescent probes (Cy3 and Cy5), 
mixing and homogenisation of the samples and application on the microarray. Subsequently, 
the relative fluorescent intensity of the signal is captured and quantified by an imaging 
software and the values are compared between patients and controls. Finally, it is obtained 
a representative plot of the ratio test versus control at different positions in the genome. The 
ratio of red fluorescence (Cy5) and green (Cy3) in each spot represents the quantity of DNA 
sample. In a situation where the amount of DNA in the test sample and in the control are 
equal the fluorescence ratio will be 1:1, showing a yellowish colour. When there are 
differences in the amount of DNA, namely gain or loss of genetic material, the proportion 
of fluorescent Cy3: Cy5 changes (89–92). 
 
 
 
 
 
 
 
 
 
The main advantage of aCGH lies in its simplicity, automation, high resolution and 
the possibility of simultaneous detection of imbalances caused by aneuploidy, deletions, 
Figure 9 - Schematic representation of the principle underling CGH microarray technology. Adapted from: Bejjani BA 
and Shaffer LG 2006 (92)  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 28 
 
duplications and/or amplifications in any locus represented on the array. Also, aCGH does 
not require cell culture neither big amounts of DNA (0.2-1.0µg, depending on the microarray 
format). The biggest limitation of arrays lies in the fact that it do not discriminate potentially 
pathogenic loci of segmental duplications that are often found in the genome of normal 
individuals and thus can induce a wrong interpretation of the results. Moreover, aCGH is not 
capable of detecting balance chromosomal abnormalities, such as balanced translocations, 
insertions, inversions neither triploidies (89,91). 
Array CGH has been considered a useful tool in research. Through this technique is 
possible to identify DNA copy number profiles for various cancers which are widely 
associated with multiple gains and losses of total/partial chromosomal regions. Since aCGH 
does not require cell culture and metaphase chromosomes, it is considered a highly desired 
technique for studding genetic patterns of solid tumours, which access directly the DNA 
content and link it to any possible dosage alteration to chromosome abnormalities. 
Furthermore, the hope lies in the discovery of associations between these profiles and 
prognostic markers that will be helpful to follow-up patients and to guide clinical treatments 
(92).  
1.5.2 Multiple Ligation-dependent Probe Amplification (MLPA) assay  
Currently, most of the techniques for detecting CNVs are not capable of detecting 
deletion or duplication of a single exon. Furthermore, these methods are time consuming, 
expensive, difficult to apply the analysis of multiple samples and require large amounts of 
DNA. The MLPA technique thus arises as an attempt to overcome some of these limitations. 
The underlying principle of MLPA is based on hybridization of two probes to the target 
sequence. Each probe is composed by one short synthetic oligonucleotide and one phage 
M13-derived long probe oligonucleotide. Both oligonucleotides have target-specific 
sequence, on 3’ end, and a universal primer sequence, on 5´end, which allows a simultaneous 
multiplex PCR amplification. One half-probe contains also a stuffer sequence of 19-370 
nucleotides between the 5 'and 3' ends that allows the differentiation during electrophoresis 
of the length of the probe itself and the size of the amplification product (93–95).  
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The main steps of the MLPA 
reaction are DNA denaturation and 
probes hybridization, ligation reaction, 
PCR amplification and detection and 
quantification of the product (130 to 
480bp) by capillary electrophoresis. In 
the first step, after addition of the two 
half-probes, they will be able to 
recognize target-specific sequences, and 
only in the presence of a match these two 
oligonucleotides will be ligated and 
amplified. Next, the PCR reaction is 
performed with only a pair of primers in 
which one of them is fluorescently labelled. Since only the ligated probes will be amplified 
in this step, the number of probe ligation products is a measure of the number of target 
sequences in the sample. Finally the products are separated by capillary electrophoresis 
following by measurement of the height of PCR derived fluorescence peaks in order to 
quantify the amount of amplification product after comparing it with control samples (93–
95).  
The results are presented as ratio DNA sample versus DNA control and if the value lies 
between 0.8 and 1.2 that means that both of the alleles are present in the sample. On the other 
hand, if values are greater than 1.2 that means that there is a gain of genetic material while 
values below 0.8 means that a loss occurred (Table 5). The control present in SALSA MLPA 
kits comprises nine control fragments: four Q fragments (64, 70, 76 and 82 nt), a 92 nt 
brenchamark probe, two D fragments (88 and 96 nt) a X fragment and a Y fragment (Table 
7) (93–95).  
 The main advantages of this assay are: (1) multiplex technique with a high 
throughput, (2) low cost and technically uncomplicated method and (3) detection of small 
rearrangements. On the other hand, the main limitations are: (1) only detect sequences 
recognized by the probes used, (2) more sensitive to contaminants and DNA degradation 
than PCR, (3) cannot be used in single cells and (4) it is not suitable for detection of unknown 
point mutations (93,96,97).  
Figure 10 - Schematic representation of the principle underling 
MLPA assay. Adapted from: Willis AS et al 2012 (180) 
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1.5.3 Methylation Specific Multiple Ligation-Dependent Probe Amplification (MS-
MLPA) assay 
In addition to be able to determinate the copy number, MS-MLPA also is useful to 
access the methylation status of up to 50 DNA sequences in a single reaction (98).  
In MS-MLPA, the probe sets 
contain many methylation-specific 
probes. The sequence targeted mentioned 
above contains a restrictions site, an 
unmethylated GCGC sequence, which is 
recognized by HhaI endonuclease. The 
mechanism underlying the MS-MLPA is 
similar to the MLPA. However, after the 
hybridization step, the mixture is divided 
into two parts, being one treated as a 
normal MLPA reaction and in the other 
HhaI is added. The enzyme will digest the 
probes hybridized to unmethylated DNA 
and the ones hybridized with methylated 
DNA remain undigested due the presence 
of methyl group. An undigested ligated 
probe will be amplified by PCR reaction, 
resulting in a normal peak signal. The amplification products (64-500nt) are separated by 
capillary electrophoresis too. The levels of DNA methylation are obtained through the 
comparison of the peak height of methylation specific probes, between DNA sample and 
control (93,98).  
The main applications of MLPA  and MS-MLPA in the field of molecular studies of 
cancer include the study of germ line deletions and/or duplications in hereditary cancers, 
analysis of somatic deletions/duplications in genes involved in tumour progression and 
response to therapy and analysis of DNA methylation, mainly as mechanism of tumour 
suppressor genes silencing (93).  
Figure 11 - Schematic representation of the principle underling 
MS-MLPA assay. Adapted from: MRC-Holland (181). 
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2 Aims 
As mentioned, larynx plays a major role in maintenance of basic features of human life 
such as communication, breathing and swallowing. Tumours in this region compromise all 
of these functions as well as other vital anatomical structures, leading to dramatic decrease 
in the patient's quality of life. On the other hand, despite the improvements observed in 
multimodal therapies, 5-year survival rates does not improved significantly.  
The study of genetic and epigenetic alterations in the progression of laryngeal cancer is 
considered to be pivotal for the development of new strategies of diagnosis and treatment, 
thus assisting in the development of personalized medicine strategies for each patient. 
However, the number of studies concerned specifically genetic alterations in LSCC is 
limited, because these tumours are usually studied as part of HNSCC. The lack of knowledge 
about this particular subject arises several problems, including the lack of correlation 
between molecular alterations and LSCC progression as well as its histophatological phases.  
Taking this into consideration, the main goal of this project is to make a genetic and 
epigenetic characterization, through array CGH, MLPA and MS-MLPA techniques, of fresh 
frozen tissue samples obtained from patients diagnosed with LSCC.  Moreover, since SALSA 
MLPA probemix P428 was originality developed for detection of copy number variations of 
genomic DNA sequences which are known to have diagnostic and prognostic importance in 
HNSCC, it is also the propose of this project to evaluate if this probemix is suitable to detect 
genetic alterations in LSCC. 
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3 Materials and Methods 
3.1 Samples 
The fresh-frozen tissue samples analysed in this study were obtained upon resection 
surgery of eight patients diagnosed with LSCC in the Department of Otorhinolaryngology - 
Head and Neck Surgery of Coimbra Hospital and University Centre (CHUC). After the 
surgery, the samples were collected from the tumour tissue in the Department of Pathology 
of CHUC. All samples were given to the Cytogenetics and Genomics Laboratory in Faculty 
of Medicine of University of Coimbra for genetic and epigenetic studies, between December 
2013 and February 2015. For each patient, one sample of tumour and non-tumour were 
collected. Patient 7 was the only one who was not possible to collect a non-tumour sample. 
Regarding the non-tumour samples, they were contralateral to the primary tumour. 
Regarding the control samples, four palatine uvulas were used in order to perform genetic 
and epigenetic analysis. Those samples were obtained upon resection surgery of patients 
diagnosed with sleep apnoea and/or snoring in the Department of Otorhinolaryngology - 
Head and Neck Surgery of CHUC. These patients did not have clinical history of cancer. 
Table 4 – Clinical Characterization of patients diagnosed with LSCC that were included in the study. (♀)-Female; (♂)-
Male; pTNM- TNM classification of Malignant Tumours 2009; NA – No data available 
Patient Sex Age Anatomical Site 
pTNM 
pT pN pM 
1 ♀ 40 Larynx T3 N2 Mx 
2 ♂ 55 Larynx T4 N0 Mx 
3 ♂ 40 Palate/Left Tonsil NA 
4 ♂ 71 Pharynx NA 
5 ♂ 64 Larynx NA 
6 ♂ 60 Supraglottic T4 N2c Mx 
7 ♂ 61 Epiglottis T3 Nx Mx 
8 ♂ 69 Hypopharynx T3 N2 Mx 
3.2 DNA extraction 
Genomic DNA was extracted from fresh frozen tissues using High Pure PCR Template 
Preparation Kit (Roche GmbH, Manmheim, Germany), according to the manufacture’s 
recommendations (99).  
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3.3 DNA quantification and assessment of DNA purity 
After DNA extraction, DNA quantification (ng/µL) and its purity were assessed by 
spectrophotometer NanoDrop-1000 (Thermo Fisher Scientific, Wilmington, USA) using 
2µL of sample. The DNA purity was evaluated using the values of the ratio between 
absorbance at 260 nm and 280 nm (A260/A280) and between absorbance at 260 nm and 230 
nm (A260/A230). The DNA is considered to be pure when value of the ratio A260/A280 is 
approximately 1,8 and the value of the ratio A260/A230 is between 1,8 and 2,2 (100). 
3.4 Array CGH (comparative genomic hybridization) 
Copy number variation (CNVs) of the samples were assessed through Agilent 
Oligonucleotide Array-Based CGH for Genomic DNA Analysis (Agilent Technologies, 
Santa Clara, California, USA) according to the manufacture’s recommendations (101). 
Array CGH was carried out using an Agilent SurePrint G3 Human Genome microarray 180K 
(Agilent Technologies, Santa Clara, CA, USA), an oligonucleotide microarray containing 
approximately 180,000 60-mer probes with a 17-kb average probe spacing. For each array 
CGH experiment, 1100ng of DNA were used in a total volume of 26µL. Also, for each CGH 
reaction, one sample and one sex-matched control were used and they were labelled with 
Cy5 and Cy3 respectively. The fluorescent DNA labelling was followed by purification and 
the degree of labelling was accessed by NanoDrop-1000 (Thermo Scientific, Wilmington, 
USA). The expected specific activity of Cy3 or Cy5 labelled samples with a 1µg input of 
gDNA is 25-40 pmol/µg and 20-35 pmol/µg respectively. The followed steps include clean-
up, hybridization and microarray wash. During the clean-up, the excess of primers and 
nucleotides were removed using Amicon 30-kDA individual filters (Millipore, Billerica, 
MA, USA). After, Cy5-labelled tumour sample and Cy3-labelled control were combined 
with Human Cot-1 DNA (Kreatech Diagnostics, Amsterdam, Netherlands), treated with 
Agilent blocking agent and 2x Hi-RPM buffer and hybridized in a 4x180K oligonucleotide 
slide, at 65 °C for 24 h in a hybridization oven (Agilent Technologies) at a constant rotation 
of 20 rpm. The hybridized slides were scanned with a microarray scanner (scanner C, 
Agilent) and the data was processed with the Feature Extraction software v10.7. The data 
from the slide images was analysed using an aberration calling algorithm, ADM-2, and a 
threshold filter that requires at least three contiguous probes. Finally, the results were 
analysed using Agilent Genomic Workbench v6.5.  
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In this project, eight fresh frozen tissue tumour samples and two controls sex-matched 
were analysed.  
3.5 Multiplex Ligation-dependent Probe Amplification (MLPA) Assay 
CNVs were also assessed by MLPA assay, following the protocol MLPA protocol for 
the detection and quantification of nucleic acid sequences - MLPA DNA Protocol version 
MDP-005 (MRC-Holland, Amsterdam, The Netherlands) and the manufacture’s 
recommendations (95). The probemix used to detect copy number changes in the samples 
was SALSA MLPA probemix P428 (MRC-Holland, Amsterdam, The Netherlands) which 
contains 41 probes for 12 different chromosomal regions that have been suggested to have 
clinical and/or prognostic relevance for HNSCC.  This kit also contain 11 reference probes 
which detect 10 different autosomal chromosomal locations that have been suggested as 
being relatively quiet in HNSCC (Figure 12) (32,37,50,102–113).  
In order to ensure the presence of sufficient DNA for analysis it was used a total 
volume of 5µL with approximately 100ng of DNA which were heated at 98ºC for 10 
minutes. Next, the probemix was added to the samples following by its heating at 95ºC for 
1 minute and its incubation for 15h at 60ºC. After hybridization, the ligation reaction was 
performed for 15 minutes at 54ºC following by inactivation of ligase enzyme and multiplex 
PCR reaction (35 cycles of 30s at 95ºC, 30s at 60ºC and 1min at 72ºC). All the reactions 
were carried out in the thermal cycler ABI 2720 (Applied Biosystems, Foster City, CA, 
USA). After PCR amplification, 1µL of sample and 9,4µL of mixture RoxTM plus HiDi 
formamide (Applied Biosystems, Foster City, USA) were applied in order to allow the 
correct fragment separation by capillary electrophoresis through ABI PRISMTM 3130 
Genetic Scan (Applied Biosystems, Foster City, USA). For each MLPA experiment, three 
controls and one negative control were used. The obtained electropherograms were analysed 
using the software GeneMapper v4.1 (Applied Biosystems, Foster City, USA) and the 
software Coffalyser.Net (MRC-Holland, Amsterdam, The Nertherlands) displayed the ratio 
between tumour samples and controls. The interpretation of ratio values was done according 
to Table 5. 
Table 5 - Interpretation of MLPA results given by Coffalyser.Net 
Ratio Copy number status 
≥ 1,2 Numerical Gain/Amplification 
0,8-1,2 Normal 
< 0,8 Numerical Loss  
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In this project, eight fresh frozen tissues tumour and seven non-tumour samples and 
four controls were analysed by MLPA. 
3.6 Methylation-Specific Multiplex Ligation-dependent Probe Amplification 
(MS-MLPA) Assay 
As mentioned, MS-MLPA assay is a modification of the conventional MLPA assay. 
In addition to detect CNVs, it also assesses the methylation status of a sample simultaneously 
in a single reaction. The protocol used was General MS-MLPA protocol for the detection 
and quantification of nucleic acid sequences and methylation profiling. - MS-MLPA protocol 
version MSP-v004 (MRC-Holland, Amsterdam, The Netherlands), and all the manufacture’s 
recommendations were followed (98).  
 The procedure underlying the MS-MLPA assay is similar to the MLPA assay. 
However, after the hybridization step, the mixture is divided into two parts, being one treated 
as a normal MLPA reaction and in the other restriction HhaI endonuclease (Promega, 
Madison, USA) is added. The probemix used was SALSA MS-MLPA probemix ME001-C2 
Tumour suppressor-1 (MRC-Holland, Amsterdam, The Netherlands), which contains 26 
probes that are able to detect the methylation status of 24 different tumour suppressor genes 
that are frequently silenced by methylation in tumours. Also, this probemix contains 15 
reference probes which are not sensitive to Hha1 activity. Besides that, all 41 probes are able 
to detect copy number variations (Figure 12) (114–119). 
The interpretation of the copy number variation was made as described in MLPA 
assay. The level of methylation percentage was evaluated using the values provided by the 
software Coffalyser.Net (MRC-Holland, Amsterdam, The Nertherlands). Thus, samples 
with genes in which the methylation percentage is greater than 20% were considered to be 
methylated. 
In this project, eight fresh frozen tissues tumour and seven non-tumour samples and 
four controls were analysed by MS-MLPA. 
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4 Results 
4.1 Array CGH (comparative genomic hybridization) 
 Eight fresh-frozen samples were analysed through Array CGH and the results 
showed several structural rearrangements. With the data given by Feature Extraction 
software v10.7 and Agilent Genomic Workbench v6.5, a human ideogram showing a 
summary of chromosomal gains and losses was built (Figure 13). Overall, the majority of 
the chromosomal alterations detected were gains, especially on chromosome 3q, 6p25.3, 8q, 
11q, 14q13.1 and chromosome X. However, significant losses of genetic material were also 
observed, namely in chromosomes 3p, 6q, 8p, Yp and Yq. The minimal common regions 
that were found amplified among patients were 3q26.1 (8/8), dup(3)(q26.33q27.3) (6/8), 
3q29 (6/8), 6p25.3 (6/8), 8q24.21 (6/8), 11q13.3 (6/8), 14q13.1 (5/8), Xp22.31 (4/8) and 
Xq21.1 (5/8) while the minimal common regions that were found deleted were 
del(3)(p26.3p12.1) (3/8), del(6)(q24.3q27) (3/8), 8p23.1 (7/8), 8p11.22 (4/8), 9p23.1 (3/8), 
12p13.31 (3/8), del(Y)(p11.32p11.2) (4/7) and del(Y)(q11.21q11.221) (7/7) (Table 6). In 
one patient there was total loss of chromosome 3 short arm and overall amplification of its 
long arm.  
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Table 6 – Summary of the most common chromosomal alterations detected by Array CGH. (Chr) – Chromosome; (*) – 
Presence of several genes in chromosomal regions which are common variants in healthy people 
Chr 
Array CGH findings 
Size (bp) Genes 
Gains Losses 
3 
 
del(3)(p26.33
p12.1) 
86,390,377 
CHL1, VHL, RARβ, RASSF1, 
MLH1, CTNNβ1, ALS2CL, 
HESRG, LRTM1, FHIT, GBE1 
3q26.1  26,568 No genes 
dup(3)(q26.33
q27.3) 
 4,364,765 
DCUN1D1, LAMP3, MCCC1, 
EIF4G1, PIK3CA 
3q29  2,717,766 MUC20, MUC4, TNK2 
6 
6p25.3  34,297 * 
 
del(6)(q24.3q
27) 
23,442,704 * 
8 
 8p23.1 483,767 Defensin family 
 8p11.22 125,449 * 
 8q24.21 327,790 MYC, PVT1, MIR1204, ASAP1 
9 9p21.3  181,477 CDKN2A, CDKN2B 
11 11q13.3  225,686 ANO1, FADD, PPFIA1, CTTN 
12  12p13.31 505,76 No genes 
14 14q13.1  72,265 SNX6 
X 
Xp22.31  19,254 VCX3 
Xq21.1  1,985 MAGT1 
Y 
 
del(Y)(p11.32
p11.2) 
733,1100 CD99 
 
del(Y)(q11.21
q11.221) 
80,064 No genes 
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4.2 Multiplex Ligation-dependent Probe Amplification (MLPA) Assay 
Eight fresh-frozen tumour tissues samples and seven non-tumour samples were 
genetically characterized by MLPA using SALSA MLPA probemix P428. The obtained 
electropherograms, which were analysed using the software GeneMapper v4.1, showed a 
peak pattern for each sample.  
The quality control of MLPA reaction is ensured by the presence of nine control 
fragments: 
Table 7 - MLPA quality control fragments (95) 
Control fragments 
Length 
(nucleotides, nt) 
Interpretation 
92 nt brenchmark 
probe 
92 
Normal probe used to compare the other 
quality control fragments. 
Q-fragments 64, 70, 76 and 86 
High when DNA amount is insufficient or 
the ligation reaction failed 
When all Q-fragment are greater than ⅓ 
(33%) of the 92 nt control fragment means 
that DNA quantity is too low. 
D-fragments 88 and 96 
Low when occurred a poor DNA 
denaturation. When the signal is inferior to 
40% of the 92 nt control fragment means 
that there were problems in the DNA 
denaturation process. 
X and Y fragments 100 and 105 Control for sample exchange. 
 
As mentioned, for each MLPA reaction, three reference samples and one negative 
control are used. Regarding the control samples, they should present a MLPA peak pattern 
of DNA sample without any genomic abnormalities (Figure 14). Since the negative control 
does not have DNA, the Q-fragments are greater than 33% of the 92nt control fragment.  
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Figure 14 – Electropherogram of a female control sample analysed by MLPA using SALSA MLPA probemix P428. * - reference probe 
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 In patient 7, the comparison between reference controls and the sample showed an 
increase of the peaks corresponding the genes EGFR – exon 10a (7p11.2), EGFR – exon 28 
(7p11.2), MYC (8q24.21), WISP1 (8q24.22) and PTK2 (8q24.3) and decreased peaks 
corresponding to the genes FHIT (3p14.2), WHSC1 (4p16.3), ABCB1 (7q21.12), MET 
(7q31.2), GATA4 (8p23.1-p22) and MTUS1 – exon 3 (8p22) (Figure 15). 
 
4.2.1 Copy Number Variations 
4.2.1.1 Tumour Samples 
Regarding the tumour samples, 90% (7/8) of the patients had copy number variations 
in several genes while patient 6 did not have any alteration (Table 9). Among the 52 gene 
probes, 12 genes did not present any alteration (Table 8): WFS1 and CD38 in chromosome 
4p, WDR36 and BTNL3 in chromosome 5q, ATM in chromosome 11q,  BRCA2 and RB1 in 
chromosome 13q and the reference probes DPYP (1p21.3), RPIA (2p11.2), PKHD1 
(6p21.2), NOS1 (12q24.22) and POMT2 (14q24.3). 
Overall, the genetic profile of these tumour samples was mainly characterized by 
gains of genetic material, especially on chromosomes 3q (4/8), 8q (6/8) and 11q (5/8). The 
loss of genetic material was higher in chromosomes 3p (4/8) and 8p (4/8).  
 The gene MYC (8q24.21) had the highest number of genetic imbalances in which 
75% (6/8) of the patients presented gain of genetic material. The second most common 
alteration was gain of genetic material in FADD – exon 1 (11q13.3) and PRPF31 (19q13.42) 
in 62,5% (5/8) of patients. The genes MCCC1 (3q26.33), WISP1 (8q24.22), PTK2 (8q24.3) 
and FADD – exon 2 (11q13.3) were exclusively amplified in 50% (4/8) of the patients which 
means that no deletions were observed in all the samples studied. GATA4 (8p23.1-p22) was 
lost in 50% of the patients. Although MTUS1 – exon 3 had the same genetic alteration rate 
(50%), patient 8 presented loss of genetic material while patients 1, 3 and 5 presented gain 
of it. The genes PIK3CA (3q26.33), CCND1 (11q13.3), FGF4 (11q13.3), CTTN (11q13.3) 
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Figure 15 - Electropherogram of a LCSS sample from patient 7 analysed by MLPA using SALSA MLPA probemix P428. (●)-Gain of genetic 
material; (●)-Loss of genetic material. 
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and PEX13 (2p16.1) were exclusively amplified in 37,5% of the patients. Regarding FHIT, 
it was the gene that have the highest rate of exclusive losses of genetic material among the 
patients included in this study (37,5%) (Figure 16).  
 
Figure 16 - The most common genetic imbalances in eight patients diagnosed with LSCC detected using SALSA MLPA 
probemix P428. (■) – Gain of Genetic Material; (■) – Loss of Genetic Material; * – Reference probe 
Although CSMD1 (8p23.3), MTUS1 – exon 1 (8p22) and H2AFX (11q23.3) present 
genetic alterations in 37,5%, it was observed both loss and gain of genetic material in these 
three genes: (1) CSMD1: lost in patients 1 and 3 and gained in patient 8; (2) MTUS1 – exon 
1: lost in patients 3 and 5 and gained in patient 8 and (3) H2AFX: lost in patient 5 and gained 
in patients 3 and 8 (Table 9). 
In addition, gain of the genes CCNL1 – exon 3 (3q25.31), TP63 (3q28), EGFR – exon 
10 and 28 (7p11.2), SPG11 (15q21.1) and PPIL2 (22q11.21) was observed in 25% (2/8) of 
the patients while the gain of  CCNL1 – exon 11 (3q25.31), CDK6 (7q21.2) MTUS1 – exon 
2 (8p22), KCNRG (13q14.3), SMAD2 (18q21.1) SMAD4 (18q21.2) and LRRFIP1 (3q37.3) 
was present in 12,5% (1/8). Loss of the gene DEPDC1B (5q12) was present in 25% (2/8) of 
the patients while RARβ (3p24), RASSF1 (3p21.3), CHEK1 (11q24.2), GALR1 (18q23) and 
USP25 (21q21.2) were lost in 12,5% (1/8) of the patients. Finally, ABCB1 (7q21.12), 
WHSC1 (4p16.3) and MET (7q31.2) presented loss in one patient and gain in another one: 
(1) WHSC1: gain in patient 3 and lost in patient 7 and (2) ABCB1 and MET: both lost in 
patient 7 and gained in patient 8 (Table 9). 
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4.2.1.2 Non-Tumour Samples 
Regarding all the seven non-tumour samples, 42,9% (3/7) of them were normal 
(patients 1, 6 and 8), without any gene or reference probe altered. Among the other non-
tumour samples, it was the gain of PRPF31 (2/7) the variation more common. Finally, 
alterations in the genes PIK3CA (3q26.33), CDK6 (7q21.2), SMAD2 (18q21.1), SPG11 
(15q21.1) and USP25 (21q21.1) occurred in 14,3% (1/7) of the non-tumour samples (Table 
9). 
It is important to notice that, in some patients, the same alteration appears in both 
tumour and non-tumour samples. For example, in patient 5, PIK3CA is amplified in both 
tumour and non-tumour samples. Also, in patients 2 and 3, the gain of PRPF31 is also 
present in tumour and non-tumour samples (Table 9). 
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Table 8 - Summary of genetic imbalances detected by SALSA MLPA probemix P428. Chr – Chromosome; (T)-Tumour 
Sample; (NT)-Non-tumour sample; * - Reference probe; (■) – Gene probe without any alteration in both tumour and non-
tumour samples. 
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Table 9 – Summary of genetic imbalances detected by MLPA in all the 8 patients included in this study. (Chr) -
Chromosome; (T)-Tumour Sample; (NT)-Non-tumour sample; * - Reference probe; (■) – Gain of Genetic Material; 
(■) – Loss of Genetic Material 
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 48 
 
4.3 Methylation-Specific Multiplex Ligation-dependent Probe Amplification 
(MS-MLPA) Assay 
Eight fresh-frozen tumour tissue samples and seven non-tumour samples were also 
analysed by MS-MLPA using SALSA MS-MLPA probemix ME001-C2. 
The analyses of electropherograms given by MS-MLPA assay is similar to the one 
described in MLPA. However, for each MS-MLPA reaction, two eletropherograms are 
generated: one corresponding to CNVs (Figure 17) and the other corresponds to methylation 
profile of the samples which were digested with HhaI (Figure 18).  
Regarding the methylation electropherogram, only the gene probes which do not have 
restriction site for HhaI or the methylated genes are amplified in PCR reaction and so, they 
are able to create a peak (Figure 18).  
 
 
 
 
 
4.3.1 Copy Number Variations 
4.3.1.1 Tumour Samples 
Regarding the eight tumour samples, all of them presented several genetic 
imbalances. Among all 41 gene probes (Table 10), six of them did not present any change 
(Table 10): CASP8 (2q33.1), CD44 (11p13), BRCA2 – exon 1 and BRCA2 – exon 22 
(13q13.1), CHFR (12q24.33) and HIC1 (17p13.3). 
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Figure 17 – CNVs electropherogram of a LCSS sample from a male patient analysed by MS-MLPA using SALSA MS-MLPA probemix 
ME001-C2. (●)-Gain of genetic material; (●)-Loss of genetic material; *-reference probe. 
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Overall, the genetic profile of these tumour samples was characterized mainly by 
losses of genetic material, especially on chromosomes 3p (6/8), and 9p (5/8). The gain of 
genetic material occurred mainly on chromosomes 12p (6/8) and 17q (5/8).  
The most common genetic alteration was the gain of TNFRSF1A (12p13.2) which 
was present in 75% (6/8) of the patients. Although CDKN2A was also altered in six patients, 
it did not present only one type of genetic alteration, being lost in five patients and gained in 
one patient. The second most common exclusive variation was the gain of BRCA1 
(17q21.31) in 62,5% (5/8) of the patients. The genes CTNNβ1 (3p21), FHIT (3p14.2) and 
CDKN2B (9p21) were lost in 50% (4/8) of the patients while CADM1 (11q23.2) and RARβ 
(3p24.2) were lost in 37,5% (3/8) of the patients. On the other hand, the gain of CDKN1B, 
(12p13.1-p12) and CD27 occurred in 50% of the patients while the gain of TIMP3 (22q12.3) 
and CDH1 (16q22.1) occurred in 37,5% (3/8) of the patients (Figure 19). Regarding VHL 
(3p25.3), three of the patients (5, 7 and 8) presented loss of genetic material while another 
one (patient 4) present gain of it (Table 11).  
Although CASR (3q21.1) and PARK2 (6q26) showed a genetic alteration rate of 
37,5%, both of them showed both gain and loss of genetic material. Taking this into 
consideration, patients 6 and 8 presented loss of CASR while patient 3 presented gain of it. 
Regarding PARK2, patients 1 and 3 present loss of genetic material while patient 6 present 
gain of it. (Table 11) 
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Figure 19 - The most common genetic imbalances in eight patients diagnosed with LSCC detected using SALSA 
MS-MLPA probemix P428. (■) – Gain of Genetic Material; (■) – Loss of Genetic Material; * – Reference probe 
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In addition, loss of MLH1 (3p22.2), RASSF1 (3p21.31), APC (5q22.2) and ESR1 
(6q24-q27) was present in 25% (2/8) of the patients while TP73 (1p36.32), DAPK1 
(9q21.33), CELF2 (10p14) and CDH13 (16q23.3) were in 12,5% (1/8) of the patients. On 
the other hand, CREM (10p12.1) and KLK3 (19q13.33) were gained in 25% of the patients 
whereas CDK6 (7q21.3), ATM (11q22.3), MLH3 (14q24.3) and TSC2 (16p13.3) were gained 
in 12,5% (1/8) of the patients. (Table 11). 
Finally, the genes KLLN (10q23.3), GSTP1 (11q13.2) and BCL2 (18q21.33) were 
altered in 25% of the patients. However, all of them presented both gain and loss of genetic 
material in different patients. Patient 6 had loss of KLLN while patient 8 had gain of it, gain 
of GSTP1 occurred in patient 4 while its loss occurred in patient 5 and finally, BCL2 was 
lost in patient one and gained in patient 5 (Table 11).  
4.3.1.2 Non-Tumour Samples  
Regarding all the seven non-tumour samples, just the one collected from patient 2 
did not present any changes (Table 11). Among the 41 gene probes, only 15 present genetic 
imbalances (Table 10). The most common alteration was the gain of CREM and CD27 in 
28,6% (2/7) of the patients. Although the genes VHL and GSTP1 were also altered in 28,6% 
of the patients, both gain and loss of genetic material were detected. Regarding VHL, patient 
3 presented gain of genetic material while patient 4 presented loss of it. GSTP1 was lost in 
patient 5 and amplified in patient 8. Finally, RASSF1, FHIT, APC, TIMP3, CDH1 and KLK3 
were gained in 14,3% (1/7) of the patients while CDKN2A, CHFR and PARK2 were lost in 
14,3% of the patients (Table 11).  
As in MLPA, MS-MLPA also revealed that some patients presented with the same 
alterations in both tumour and non-tumour samples: (1) Patient 1 - loss of PARK2 and gain 
of KLK3; (2) Patient 3 - gain of CDH1; (3) Patient 5 - loss of GSTP1; (4) Patient 6 - gain of 
CREM and (5) Patient 8 - loss of CDKN2A and gain of CD27. In addition, MS-MLPA also 
revealed that in patient 4 there was a gain of VHL in the tumour sample while the non-tumour 
samples presented loss of it (Table 11).  
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Table 10 - Summary of genetic imbalances detected by SALSA MS-MLPA probemix ME001-C2. (Chr) – Chromosome; 
(T)-Tumour Sample; (NT)-Non-tumour sample; * - Reference probe; (■) – Gene probe without any alteration in both 
tumour and non-tumour samples. 
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Table 11 - Summary of genetic imbalances detected by MS-MLPA in all the 8 patients included in this study. (Chr)-
Chromosome; (T)-Tumour Sample; (NT)-Non-tumour sample; * - Reference probe; (■) – Gain of Genetic Material; (■) – 
Loss of Genetic Material 
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4.3.2 Methylation Profile 
The cut-off used to define a gene as methylated was having a methylation percentage 
above 20%. Taking this into consideration, all the reference samples as well as the non-
tumour samples revealed to be unmethylated while only 50% of the tumour samples showed 
one or two genes methylated.  
Among the samples with an altered methylation pattern, CHFR was the gene more 
frequently altered (25% of the patients). The genes RARβ, RASSF1 and CDKN2A were 
methylated in 12,5% (1/8) of the patients. 
 
Table 12 – Summary of the results obtained for the samples with a methylation pattern altered 
Chromosome Gene Methylation (%)* 
Alterations 
[Number of patients (%)] 
3p24.2 RARβ 31% 1/8 (12,5%) 
3p21.31 RASSF1 22% 1/8 (12,5%) 
9p21.3 CDKN2A 61% 1/8 (12,5%) 
12q24.33 CHFR 28% and 22% 2/8 (25%) 
 
*Unmethylated gene: (%) < 20%; Methylated gene: (%) ≥ 20% 
  
 
 
  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 55 
 
5 Discussion 
Laryngeal squamous cell carcinoma (LSCC) is one of the most common 
malignancies in head and neck cancer family and despite the recent therapeutic and 
diagnostic advances, the overall 5-year survival rate did not improved much in the last years. 
Although there is a clear lack of precise genetic information, it has been accepted that LSCC 
arises from accumulation of genetic alterations which leads to genomic instability. Taking 
this into consideration, genetic studies arise as potential tool to understand the disease in 
order to develop new diagnostic methods to detect the tumour in an early stage and to 
develop personalized therapeutic strategies. 
In order to characterize genetically and epigenetically all the samples of this study, 
the DNA was extracted and copy number variations was assessed through aCGH, MLPA 
and MS-MLPA while the methylation profile was analysed through MS-MLPA. 
5.1 Assessment of Copy Number Variations 
 Among the eight fresh-frozen samples analysed, aCGH results revealed that the gain of 
genetic material was the most common alteration, especially in chromosomes 3q, 6p, 8q, 
11q, 14q and chromosome X. Regarding losses, the chromosomes more affected were 3p, 
6q, 8p, 9p, 12p, Yp and Yq. However, it is important to know that aCGH do not descrimite 
potential pathogenic structural variations from common structural variations present in 
healthy people. In order to identify potential chromosomal alteration that might have a role 
in laryngeal carcinogenesis, all common variations were excluded from the analyses using 
the “Database of Genomic Variants: A curated catalogue of human genomic structural 
variation” (120). Among the seventeen minimal common regions mentioned in Table 6, six 
alterations were immediately excluded due to the presence of many common variations in 
healthy controls samples already described: 3q26.1, 6p25.3, del(6)(q24.3q27), 8p23.1, 
8p11.22 and 12p13.31.  
  With the exception of the chromosomal region Yq11.21-Yq11.221, all the other ten 
regions code for many genes that have been described as having a role in carcinogenesis. All 
of them will be discussed individually in the following sections.  
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5.1.1 Chromosome 3 
5.1.1.1 Region 3p 
 In head and neck cancer, the loss of the short arm of chromosome 3 is frequently 
followed by gain of its long arm, leading to the formation of isochromosome 3q. This 
alteration has already been seen in head and neck carcinoma as well as laryngeal carcinoma 
(33,121). However, the presence of isochromosomes can only be confirmed by karyotype or 
FISH (Fluorescent In Situ Hybridization). Nevertheless, the loss of 3p and gain of 3q lead 
to deletion of tumour suppressor genes and amplification of oncogenes, respectively.  
 Loss of the short arm of chromosome 3 is one of the earliest and most frequent changes 
in head and neck carcinoma, being present in dysplasia lesions (33,121). The partial loss of 
del(3)(p26.3p12.1) was also one of the most common events found in this study. This region 
codes for several genes whose role in laryngeal carcinogenesis has been already reported. 
The results of MLPA and MS-MLPA together showed a higher percentage of genetic 
alterations in FHIT, CTNNβ1 and VHL genes. Among these genes, FHIT is commonly found 
to be deleted and the loss of function leads to abnormal cell proliferation and resistance to 
apoptosis, thus contributing to the formation of a tumour (33,35,121).  
 Loss of CTNNβ1 has been associated with tumour invasion and metastasis (37,39,41). 
Álvarez-Marcos et al. (2012) established a positive relationship between loss of CTNNβ1 
and cytoplasmic β-catenin overexpression. They suggested that mutations or dysregulation 
of the gene might lead to change of protein location which ultimately might promote loss of 
cell-cell adhesion. This alteration was observed in laryngeal epithelial precursor lesions 
which may suggest that loss of CTNNβ1 has a role in malignant transformation phenotype 
(122). 
 Zhang et al. (2014) found a significant correlation between VHL (von Hippel-Lindau 
tumour suppressor, E3 ubiquitin protein ligase) loss and epithelial-mesenchymal transition 
in oral squamous cell carcinoma, thus affecting the prognosis of the patient. Through the re-
expression of VHL in cells, Zhang et al. (2014) demonstrated that the cells have a lower 
capacity of proliferation, migration and invasion. Taking this into consideration, the VHL 
may play a role in invasiveness and metastasis. In healthy people, VHL is involved in 
degradation of HIF-1α (hypoxia-inducible factor 1α). In hypoxic tumours, the loss of VHL 
may lead to accumulation of HIF-1α which is followed by synthesis of HIF-1 that is involved 
in angiogenesis (123,124). 
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 Loss of MLH1, RARβ and RASSF1 was detected more frequently by aCGH than by 
MLPA and/or by MS-MLPA. This fact may be explained by the different sensitivities of the 
three techniques in the analyses of tumour samples which are contaminated by normal cells. 
The loss of MLH1, RARβ and RASSF1 has already been stablish in several types of tumours, 
including head and neck carcinoma and some of them in laryngeal carcinoma (33,121). 
Marcos et al. (2011), who also used MLPA to analyse LSCC samples, found out that loss of 
MLH1 was one of the most common alterations in patients diagnosed with LSCC (31). 
Lee et al. (2010) was the first to identify ALS2CL (ALS2 C-terminal like) as a potential 
suppressor tumour gene in head and neck cancer. In previous studies, this alteration was 
reported in breast and colorectal cancers (125). 
 Gollin et al. (2014) also, through a meta-analysis study, identified the loss of ESRG 
(embryonic stem cell related (non-protein coding)), LRTM1 (leucine-rich repeats and 
transmembrane domains 1) and GBE1 (glucan (1,4-alpha-), branching enzyme 1) in 
chromosome 3p (121). Although the first two genes do not have a known function, GBE1 
has a role in carbohydrate metabolism and its loss has been associated with 
chemoradioresistance in breast cancer and so to a poorer prognosis (126).  
 Although loss of CHL1 (cell adhesion molecule L1-like) has not been associated with 
laryngeal carcinoma, this variation has already been reported in oral, esophageal and breast 
squamous cell carcinomas (127,128). CHL1 [Uniprot: O00533] belongs to the family of L1 
neural cell adhesion molecules that plays a role in nervous system development and in 
synaptic plasticity. However, this gene has been considered as a potential suppressor tumour 
gene since its overexpression seems to suppress cell proliferation and invasion while its 
knockdown leads to an increased proliferation and invasion in vitro as well as promotion of 
tumour formation in vivo (128). Uchida et al. (2011) proposed that loss of CHL1 might be 
and indicator of aggressiveness of oral cancer (127).  
5.1.1.2 Region 3q 
 Alongside with loss of 3p, the gain of 3q is also one of the most frequent alterations in 
HNSCC. Within 3q, two smaller fragments were considered to be minimal common regions 
that were found to be amplified in aCGH: dup(3)(q26.33q27.3) in 6 out of 8 patients and 
3q29 in 7 out of 8 patients. Moreover, these alterations have been associated with a poor 
clinical outcome (121).   
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 The gain of the genes MCCC1 and PIK3CA, which are mapped within 3q26.33-q27.3, 
was a frequent event detect by MLPA and MS-MLPA and, overall, the results are supported 
by aCGH. PIK3CA is an oncogene whose gene product is able to stimulate AKT signalling 
which is involved in growth factor independent growth, cell invasion and metastasis (121). 
Redon et al. (2002) observed PIK3CA amplification in precancerous oral dysplasia, 
suggesting that this event may be involved in early head and neck cancer (129). Gain of 
PI3KCA leads to PI3K-Akt-mTOR aberrations which will promote a malignant phenotype 
by supressing immune system and inflammation and by promoting angiogenesis, survival, 
invasion and metastasis (130). Regarding MCCC1, its amplification has been seen in lung 
and oral squamous cell carcinomas (131,132) 
 Other candidate genes within 3q26.33-3q27.3 which are found to be amplified in head 
and neck cancer include DCUN1D1, LAMP3 and EIF4G1. 
 Sarkaria et al. (2006) suggested that DCUN1D1 was a candidate oncogene due to its 
ability to transform cells fibroblastic and keratinocytic lineage. Also, they used shRNA 
against DCUN1D1 which resulted into apoptosis of cancer cell lines carrying the amplified 
gene, suggesting that DCUN1D1 overexpression may also has a role in maintenance of 
malignant phenotype (133).  
 The expression of LAMP3 (Lysosomal associated membrane protein 3), which is a 
downstream target of TP53, has been associated with hypoxia-induced metastasis and poor 
overall survival in both cervical and breast cancers (134,135). In addition, Nagelkerke et al. 
(2011) suggested also that the overexpression of LAMP3 may be a biomarker for hypoxia 
mediated treatment resistance in breast cancer. Although the amplification of LAMP3 has 
already been reported in laryngeal carcinoma (32), its role in laryngeal carcinogenesis is still 
needed to be clarified.  
 EIF4G1 (eukaryotic translation initiation factor 4 gamma, 1), a member of the 
translational initiation factor family, is over-expressed in head and neck cancer, including 
nasopharyngeal and hypopharyngeal carcinoma as well as in lung squamous cell carcinoma 
(136–138). In nasopharyngeal carcinoma, Tu et al. (2010) found a significant association 
between EIF4G1 over-expression and lymph node involvement, suggesting that this 
alteration was a poor prognosis factor in nasopharyngeal carcinoma. In addition, they found 
that EIF4G1 promoted tumourigenesis in vivo and they proposed that EIF4G1 may play a 
role in cell proliferation, cell cycle, migration and invasion (137). 
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 Finally, the last chromosomal segment identified by aCGH as a minimal common 
region amplified in chromosome 3 is 3q29. Although both MLPA and MS-MLPA do not 
have gene probes for this regions, several genes have been identified as having a role in head 
and neck carcinogenesis (MUC4, MUC20 and TNK2). 
 MUC4 (mucin 4) and MUC20 code for membrane-bound glycoproteins which are 
expressed in epithelial cells and they play a role in protection, differentiation and renewal of 
epithelium as well as in cell adhesion, cell signalling and immune response. Hamada et al. 
(2012) found an association between aberrant over-expression of MUC4, nodal metastasis, 
diffuse invasion and tumour progression in oral squamous cell carcinoma. In addition, 
patients with over-expression of MUC4 appeared to have a worse overall and disease-free 
survival. MUC4 promotes tumour progression by repressing apoptosis, promoting tumour 
metastasis and escaping from immune response by masking the surface epitopes (139). 
Regarding MUC20, its overexpression has been associated with poor prognosis in colorectal 
and endometrium carcinomas (140,141). Xiao et al. (2013) showed that over-expression of 
MUC20 promoted metastasis while knockdown of the gene attenuated migration and 
invasion in colorectal cells.  
 Over-expression of TNK2 (tyrosine kinase, non-receptor, 2) has already been 
reported in lung, breast and prostate cancer. Its activation is associated with progression to 
a metastatic phenotype and its inhibition seems to lead to cell cycle arrest, apoptosis and 
sensitization to ionizing radiation (142). 
The gene probemix used in MLPA also target other genes outside the minimal 
common regions identified by aCGH, namely CCNL1 (3q25.32) and TP63 (3q28). Although 
genetic imbalances in both genes were not the most frequent alterations in MLPA, the 
chromosomal region in which CCNL1 and TP63 are mapped is, according to aCGH results, 
amplified in 37,5% and 50% of the patients, respectively. CCNL1 [Uniprot: Q9UK58] is 
involved in the regulation of pre-mRNA splicing as well as RNA polymerase II. Its 
amplification and over-expression is associated with lymph node metastases and shorter 
overall survival in HNSCC, including in laryngeal carcinoma. However, the role of 
amplification of CCNL1 in carcinogenesis remains unclear (121,143). TP63 is commonly 
over-expressed in head and neck carcinoma and it is associated with poor prognosis. 
According to Orzol et al. (2014), it was suggested that TP63 locus is a rare site for HPV 
integration in lung cancer (144). 
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 60 
 
5.1.2 Chromosome 8 
The dup(8)(q23q24) is one of the most frequent copy number alterations in early head 
and neck cancer (121,145). Array CGH allowed to identified the amplification of 8q24.21 
as one of the minimal common regions affected in the LSCC patients included in this study. 
Within this region, MYC is one of the genes whose amplification has already been associated 
with laryngeal carcinoma (33,47,48). PVT1 (Pvt1 oncogene (non-protein coding)) is 
frequently co-amplified with MYC and acts as an oncogene by up-regulation of anti-
apoptotic genes and down-regulation of genes whoso product has pro-apoptotic functions, 
thus favouring an apoptotic phenotype (146). Although PVT1 has not been associated with 
laryngeal carcinoma yet, its amplification has been seen as a poor prognosis factor in patients 
with colorectal cancers (147). PVT1 locus contain a cluster of microRNAs, such as MIR1204 
(microRNA 1204) whose depletion seems to promote the expression of anti-apoptotic genes 
(146). 
ASAP1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 1), also mapped in 
8q24, plays a role in actin cytoskeletal remodelling and focal adhesions. Li et al. (2014) 
showed that up-regulation of ASAP1 in LSCC primary tumours was associated with lymph 
node metastasis and its down-regulation lead to a decreased in the invasive potential (148).  
Other frequent alterations in chromosome 8 that were identified by MS-MLPA include 
loss of the MTUS1 and GATA4 as well as gain of genes WISP1 and PTK2.  
WISP1 and PTK2 are also mapped in the long arm of chromosome 8, close to the locus 
of MYC and PVT1. aCGH showed that the region where these genes are mapped were 
amplified in 62,5% of the patients. Jarvinen et al. (2006) found that WISP1 was 
simultaneously amplified and over-expressed in laryngeal carcinoma (32). However, its role 
in laryngeal carcinogenesis remains unclear. In oral squamous cell carcinoma, WISP1 seems 
to promote cell migration (149). Regarding PTK2, which is involved in adhesion and growth-
regulatory signal transduction, its over-expression was shown to be present in early stages 
of laryngeal carcinoma (121,145). Also Rodrigo et al. (2011) observed that patients carrying 
over-expressed PTK2 in dysplastic lesions have a higher cancer incidence. In addition, they 
showed that the frequency of PTK2 over-expression increased with the grade of dysplasia, 
which may suggest a role in malignant progression (145).  
MTUS1 and GATA4 are mapped on short arm of chromosome 8, which is found to be 
deleted in HNSCC(121). The reduced expression of MTUS1, a tumour suppressor gene that 
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inhibits cell proliferation, has been observed in colon, ovarian, pancreatic and tongue oral 
cancers. According to Ye et al. (2007), a previous mutation analysis of MTUS1 in hepatic 
cancer showed that the gene is susceptible to point mutations or small deletions which may 
explain the fact that, in this study, the tree different exons analysed by MLPA revealed 
different alteration rates. Regarding oral tongue carcinoma, loss of MTSU1 expression seems 
to be associated with an advance stage of this cancer (107). Regarding GATA4, its role in 
human cancers is unclear. The loss of this gene has been implicated in colorectal cancer, 
where Hellebrekers et al. (2009) showed that the introduction of GATA4 leaded to inhibition 
of cell growth, migration and invasion, thus suggesting a tumour suppressor function (150). 
5.1.3 Chromosome 9 
In head and neck carcinoma, loss of the band 9p21 is one of the most frequent genetic 
early stage changes. aCGH results showed that loss of 9p21.3 happened in 37,5% of patients. 
CDKN2A and CDKN2B are mapped in this sub-band.  
As mentioned, the loss of suppressor tumour gene CDKN2A has already been 
reported in head and neck cancer, as well as in laryngeal carcinoma (29,33,49). In addition, 
MS-MLPA also showed that CDKN2A was deleted in 62,5% of the patients, being one of 
the most common genetic imbalances detected.  
As CDKN2A, CDKN2B also promotes cell cycle arrest at G0/G1 checkpoint, thus 
being a negative regulator of cell cycle. Swellam et al. (2008) found that, in LSCC, deletion 
of both genes was significantly associated with increased telomerase activity and this 
correlation was associated with poor prognosis (151). 
5.1.4 Chromosome 11 
Amplification of 11q13, which was one of the most common amplifications detected 
by aCGH, has already been associated with poor prognosis in head and neck cancer. In this 
region are mapped several oncogenes and genes candidates involve in laryngeal 
carcinogenesis, namely ANO1, CCND1, CTTN, FADD, FGF4 and PPFIA1. The 
amplification of CCND1, CTTN and FADD has already be shown in laryngeal carcinoma 
(31,33,51,60,55). MLPA also revealed that those genes were frequently amplified in LSCC 
samples included in this study. In addition, MLPA also detected the amplification of FGF4 
which has a role in regulation of embryonic development, cell proliferation and 
differentiation. However, its role in human carcinogenesis needs further studies (51). 
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ANO1 (anoctamin 1, calcium activated chloride channel) codes for a calcium-
dependent chloride channel whose exact role on tumourigenesis appears to be 
controversial(121,152). According to Ayoub et al. (2010), over-expression of ANO1 
stimulates cellular attachment, metastasis and invasion, but not cell proliferation (153). 
However Duvvuri et al. (2012) showed that ANO1 seems to stimulate cell proliferation (154). 
Ruiz et al. (2012) proposed that ANO1 enhances cellular motility and migration, thus 
facilitating the appearance of metastasis (152).  
PPFIA1 (protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 1) may regulate the disassembly of focal adhesions. Its 
function in laryngeal carcinogenesis is poorly understood (32,51). Tan et al. (2008), through 
siRNA and in vitro invasion assays, found that when PPFIA1 levels were reduced, invasion 
of HNSCC cells was increased, thus suggesting a potential role in invasion (155). 
CADM1 was found to be deleted in 37,5% of the patients. Marcos et al. (2010) found 
that loss of CADM1 was one of the most frequent events in laryngeal squamous cell 
carcinoma group (31). In addition, Lu et al. (2012) found that over-expression of this gene 
seemed to inhibit cell proliferation, reduce cell invasion and to induce apoptosis. Taking this 
into consideration, CADM1 appears to have tumour suppression functions in LSCC (156).  
Regarding ATM, CHEK1 and CD44, which are gene analysed by MLPA and MS-
MLPA, their frequency of genetic imbalances was low (0%-12,5%) among the samples 
included in this study and so, it is probable that they do not have a relevant role in laryngeal 
carcinogenesis. In addition, because GSTP1 and H2AFX presented both genetic gains and 
losses (12,5%-25%), they also might not have a significate role in the same pathological 
process.  
5.1.5 Chromosome 14 
In chromosome 14, a small region was found to be amplified in 62,5% of the patients: 
14q13.1. In this sub-band is mapped the gene SNX6 (sorting nexin 6) and little is known 
about its physiological function. SNX6 [Uniprot: Q9UNH7] is involved in intracellular 
trafficking as well as in EGFR and E-cadherin degradation.  
Currently, Rivera et al. (2010) establish the only association between SNX6 and 
cancer. They identified SNX6 as a binding partner of BRMS1 (breast cancer metastasis 
suppressor 1), a member of growing metastasis suppressors family which reduces breast and 
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melanoma metastasis without affecting primary tumour growth. In addition, SNX6 is capable 
of interact with TGFβ which has been largely associated with human cancer (157).  
Cetuximab (ErbituxTM, C225, ImC-225; ImClone Systems, Inc.) is a chimeric 
human/murine monoclonal antibody of the IgG1 isotype that binds to the EGFR with higher 
affinity than its natural ligands, preventing proliferation, angiogenesis, anti-apoptotic 
signalling, invasion and metastasis(158). Cetuximab is the only EGFR-targeting therapy 
approved by the Food and Drug Administration and if SNX6 degrades EGFR, perhaps 
patients with amplification and over-expression of SNX6 have a worse prognosis. Thus, 
SNX6 could be a therapeutic biomarker. 
Regarding POMT2 and MLH3 mapped in 14q and reference probes in MLPA and 
MS-MLPA, the results revealed a low frequency rate (0%-12,5%) of genetic imbalance, 
suggesting that they might not be important in laryngeal carcinogenesis. 
5.1.6 Chromosome X 
In chromosome X, two regions were found to be frequently amplified in the patients 
included in this study: Xp22.31 and Xq21.1.  
VCX3A is mapped on Xp22.31 and belongs to human testis-specific gene family 
known as VCX/Y. Although VCX3A [Uniprot: Q9NNX9] function is poorly understood, it 
may play a role in spermatogenesis and in sex ratio distortion. Taguchi et al. (2014) observed 
that VCX3A was overexpressed in lung and colon cancer cell lines (159).  
MAGT1, a gene which codes for a magnesium transporter, is mapped on Xq21.1 A 
few studies have been conducted in patients with XMEN (X-linked immunodeficiency with 
magnesium defect, EBV infection, and neoplasia) disease which may be caused by loss of 
function of MAGT1. Chaigne-Delalande et al. (2013) showed that magnesium has a major 
role in anti-tumour immunity. In addition the association between its decrease inside the cell 
and the predisposition to lymphoma onset seems to be controversial (160,161). However, 
the amplification of MAGT1 has never been reported to be associated with cancer. 
5.1.7 Chromosome Y 
The human Y chromosome is made by two pseudoautosomal regions (PAR1 and 
PAR2), which recombine with chromosome X during meiosis, and one Y-specific region 
(YSR). Genes located in chromosome Y are involved in cell cycle control, signal 
transduction, cell proliferation, protein degradation and gene expression (162).   
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Partial loss of chromosome Y and Y nullisomy has already been reported in head and 
neck cancer (162,163). However, its role in head and neck carcinogenesis remains poorly 
understood. Silva Veiga et al. (2012) showed that, although head and neck cancer has higher 
incidence in older male people, the loss of chromosome Y is independent of the onset age of 
the disease (162). 
In most of the male samples (6/7), total or partial loss of chromosome Y was 
observed, especially del(Y)(q11.21q11.221) and del(Y)(p11.32p11.2). The first region has 
no known genes mapped in it while in the second one, CD99, which is located in PAR1 
(Xp22.32 and Yp11.3), has been associated with human carcinogenesis. Regarding the only 
female patient included in this study, she present amplification of Xp22.32. 
CD99 is a glycoprotein present in cell surface whose role in human physiology 
remains unclear. CD99 has been associated with cell adhesion, morphology and death as 
well as diapedesis of leukocytes. Its loss has been associated with poor prognosis in several 
types of tumours, including osteosarcoma, gastric adenocarcinoma, pancreatic tumours and 
carcinoma of gall bladder (164,165). Jung et al. (2007) also showed that down-regulation of 
CD99 was associated with cell proliferation and migration in gastric adenocarcinoma (165). 
5.1.8 Other Genetic Imbalances 
In MLPA, the reference probe PRPF31 was found to have a high frequency 
amplification (62,5%) in tumour samples. Regarding PRPF31, which is involved in pre-
mRNA splicing, there is no reported association between this gene and human cancer yet. 
However, two patients who presented amplification of this gene in tumour sample, also had 
this alteration in the non-tumour sample, which may suggest that amplification of PRPF31 
may be an early event in laryngeal carcinogenesis.  
In MS-MLPA, other gene and reference probes were also found to have a high 
frequency amplification in tumour samples: TNFRSF1A (75%), BRCA1 (62,5%), CD27 and 
CDKN1B (50%) and CDH1 (37,5%). 
TNFRSF1A codes for a receptor of TNFα which is generally accepted to have a role 
in human carcinogenesis. Over-expression of TNFα leads to persistent inflammation, DNA 
damage and increased pro-angiogenic functions. Chronic expression of TNFα has been 
associated with lymph node involvement and poor prognosis in breast cancer. Regarding 
TNFRSF1A, its blocking seems to impair tumour survival signalling. Although a few 
functional polymorphisms have been described, the role of TNFRSF1A amplification in 
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human carcinogenesis still remains unclear (166). In addition, CD27 [Uniprto: P26842] 
which also is a member of TNF-receptor superfamily, is also amplified. Little is known about 
its biological function as it may have a role in T-cells survival and apoptosis. The correlation 
between amplification of CD27 and human cancer is still unclear.  
BRCA1 has tumour suppressor functions due to its role on DNA repair, cell cycle 
control and maintenance of genomic stability (167). However, our study showed its 
amplification which has never been reported before.  
CDKN1B is an important cell cycle regulator which mediates the progression from G0 
to G1 phases. López et al. (2013) found a decreased expression of CDKN1B in laryngeal 
dysplasia lesions (168). In addition, Bodnar et al. (2014) showed that loss of p27 expression 
was associated in poor prognosis and lymph node involvement in metastatic laryngeal 
carcinoma (169). Nevertheless, the amplification of CDKN1B found in our study has not 
been reported yet.  
TIMP3, a metalloproteinase inhibitor, has reduced expression in colon and thyroid 
cancers. In addition, Bai et al. (2007), found an association between loss of expression of 
TIMP3 and degree of malignancy, infiltration and metastasis of colon carcinoma (170,171). 
In our study it was observed a loss of genetic material in TIMP3 which no one has reported 
it yet. 
5.2 Assessment of Methylation Profile 
MS-MLPA also allows the study of the methylation profile of several genes. Since this 
project is a pilot study, only four different controls were used. None of the reference samples 
presented any genes with a methylation frequency rate above 10% and so they were 
considered to be unmethylated. In this study, a gene was considered to be methylated when 
the methylation rate was over 20%. This cut-off was establish based on laboratory 
experience in cancer research projects as well as in scientific papers: Ozdemir et al. (2012) 
used 25% as the cut-off for define a methylated gene in ovarian cancer while Verschuur-
Maes et al. (2012) and Moelans et al. (2011) used 15% in breast cancer samples (172–174). 
Nevertheless, is worth noting the importance of increasing the number of controls in this 
study in the definition of precisely the methylation cut-offs. 
MS-MLPA results revealed alterations of methylation pattern in four genes: RARβ, 
RASSF1, CDKN2A and CHFR. The silencing of these genes by promoter hypermethylation 
has already been associated with laryngeal carcinogenesis. Methylation of CDKN2A has 
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been associated with invasion lymph nodes and cell migration while CHFR has been 
associated with late stage disease (67,68). Regarding RARβ, its methylation seems to 
facilitate cell proliferation and apoptosis resistance (73). 
The physiological function of RASSF1 (Ras association (RalGDS/AF-6) domain family 
member 1) is involved with regulation of cell cycle, microtubule stabilization, cell adhesion, 
motility and apoptosis. It is a potential tumour suppressor gene due to its ability to control 
mitosis and to increase genomic stability (175). Fendri et al. (2009) reported a significant 
association between methylated RASSF1 and lymph node metastasis and advanced tumour 
stage in nasopharyngeal carcinoma (176). Moreover, Park et al. (2007) and Paluszczak et al. 
(2011) found that RASSF1 was aberrantly methylated in laryngeal squamous cell carcinoma 
(73,75). Paluszczak et al. (2011) also suggests that RASSF1 hypermethylation may promote 
uncontrollable cell growth as well as resistance to apoptosis (73).  
5.3 Comparison between aCGH, MLPA and MS-MLPA 
 Overall, the results showed that there was an agreement between the three techniques 
used. In addition, aCGH was not only able to confirm the majority of the alterations detected 
by MLPA and MS-MLPA but also revealed other genetic imbalances in the genes included 
in the probemixes used that were found to be normal using MLPA and MS-MLPA assays. 
It is important to know that the sensitivity of the three techniques is highly dependable on 
the percentage of tumour and normal cells in the sample. Taking this into consideration, it is 
possible that different results may be explained by contamination of tumour samples with 
normal cells. According to Stuppia et al. (2012), it is difficult to detect genetic imbalances 
by MLPA if the tumour sample contains more than 50% of normal cells (93). Regarding 
aCGH, Neill et al. (2010) showed that oligo platforms, such as the one used in this study, 
are able to detect mosaicism of 30% or greater as well as 10% under optimal conditions 
(177). Regarding the mosaicism, one way to avoid it would be to use laser microdissection 
to select specific cell populations of interest.  
 In addition, MLPA and MS-MLPA are techniques directed towards the identification of 
genetic imbalances in a single exon. Thus, they are not able to identify other alterations 
outside the gene probemix used. In this sense, although aCGH is not able to detect changes 
in a single exon, it adds the advantage of being able to detect new chromosomal imbalances 
through all the genome, allowing a complete coverage of the genome. Taking this into 
consideration, aCGH seems to be a more approachable technique when the main goal is to 
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identify new genetic biomarkers. However, due to its cost, aCGH is unlikely to be introduced 
in a diagnostic routine. After the identification of a set of genetic biomarkers with diagnostic, 
prognostic and therapeutic value, MLPA comes up as a more robust, faster and cheaper 
technique that allow the simultaneous analyses of multiples samples, representing a valuable 
tool easy to perform and able to detect different types of genetic alterations, including CNVs, 
methylation and point mutations, which otherwise would require multiple techniques. 
 MLPA and MS-MLPA are relative techniques that require reference probes in order to 
compare with peak pattern obtained by target-specific probes. Since cancer is a very 
heterogeneous and instable disease, one of the major problems in MLPA and MS-MLPA is 
defining reference probes which are unrelated with the condition of interest. For instance, in 
this study, reference probes such as PRPF31 and TNFRSF1A presented a high rate of 
alterations. The selection of reference probes may be hampered by chromothripsis and 
chromoplexy events. Chromothripsis is result of random chromosome shattering and 
reassembly which leads to highly mosaic chromosomes and the pieces that were not 
incorporated are lost to the cell. A single event may involve a few regions of the genome, 
leading to high local rearrangement. The difference between chromothrispsis and 
chromoplexy seems to be the number of breaking points. These events may be caused by 
chromosome segregation errors, ionizing radiation and exogenous stimuli which normally 
lead to replication stress and repeated BFB cycles. Chromothripsis may cause loss of genetic 
material, which leads to disruption of tumour suppressors, and assembly of genomic 
fragments into highly amplified circular structures (double-minute chromosomes) 
containing oncogenes, such as MYC (178,179).  
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6 Conclusions 
Overall, the aims proposed for this study were accomplished. Eight fresh-frozen tumour 
samples and seven non-tumour were genetically and epigenetically characterized by aCGH, 
MLPA and MS-MLPA. All the techniques used have proved to be complementary in the 
genetic study of cancer and revealed that: 
 Overall and as expected, aCGH was able to detect more genetic imbalances than 
MLPA or MS-MLPA and this may be explained by the difference in sensitivity of 
the techniques; 
 Gain of genetic material occurred mainly in chromosomes 3q, 8q, 11q, 14q13.1 
and X while loss of genetic material happened mainly in chromosomes 3p, 9p23.1 
and Y; 
 Among the tumour samples, the gain of MYC and TNFRSF1A were the most 
frequently genetic imbalances detected. Although the role of amplified MYC is 
well established in laryngeal carcinoma, the gain of TNFRSF1A in laryngeal 
carcinogenesis is still unclear; 
 The presence of the same genetic alteration in both tumour and non-tumour 
samples may indicate the presence of an early event in LSCC; 
 Regarding the methylation profile, methylation in RASSF1, CDKN2A and CHFR 
have already been reported as having an important role in laryngeal 
carcinogenesis. However, the role of methylated RARβ in LSCC remains 
controversial; 
 Overall, SALSA MLPA probemix P428 and SALSA MS-MLPA probemix ME001-
C2 revealed to be suitable for detection of genetic imbalances in laryngeal 
squamous cell carcinoma. However, some reference probes were frequently 
altered while a few gene probes did not present any change. Taking this into 
consideration, it is mandatory to continue the studying of genetic imbalances in 
LSCC in order to create a new probemix containing genes that have been 
considered biomarkers of LSCC. 
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7 Future Perspectives 
Head and neck squamous cell carcinoma is the sixth most common malignant tumour 
in the world and the larynx is the second most common affected organ. Laryngeal 
malignancies are mainly diagnosed in a late stage and since they are aggressive tumours that 
have a fast growth and a high tendency to develop metastasis, they have a high mortality rate 
that has not changed in the last years. Taking this into consideration, it is mandatory to 
continue the study of genetic progression that leads to development of laryngeal carcinoma 
in order to improve the life quality of the patients. This pilot study was initiated in an attempt 
to identify genetic and epigenetic biomarkers with diagnostic and prognostic meaning in 
laryngeal squamous cell carcinoma. The major limitation of this study is related with the 
reduced number of samples, both tumour, non-tumour and controls. The increase of samples 
number is mandatory in order to differentiate laryngeal carcinoma from the other tumours 
that belong to head and neck cancer family as well as to build a genetic progression model. 
Ultimately, the main goal would be to establish an association between genetic alterations 
and clinical data.  
 MLPA, MS-MLPA and aCGH revealed to be complementary in genetic study in the 
field of cancer. However, the use of one probemix for MLPA and another for MS-MLPA is 
not enough to establish a genetic alteration pattern in LSCC patients. Taking in consideration 
the probemixes available, a new one should be created in order to detect genetic imbalances 
in LSCC with more accuracy which, ultimately, will help to identify a specific set of genes 
with diagnostic, prognostic and therapeutic value in order to reduce the incidence and 
mortality rates. In addition, since DNA hypomethylation contributes significantly to 
oncogenesis, the study of hypomethylated oncogenes should also be included in the analyses 
of the samples.  
 
   
 
  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 73 
 
8 Bibliography 
1.  Mescher AL. Junqueira’s Basic Histology: Text & Atlas. 13th ed. McGraw-Hill; 
2013.  
2.  National Cancer Institute - U.S. Department of Health and Human Services. What 
You Need To Know About Cancer of the Larynx . 2014 [Accessed on 2014 Dec 19]. 
Available from: http://www.cancer.gov/publications/patient-
education/WYNTK_larynx.pdf 
3.  Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran’s Pathological Basis 
of Disease. 6th ed. Elsevier Health Sciences; 2009.  
4.  Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol 
Life Sci. 2011;68(10):1681–702.  
5.  Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.  
6.  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646–74.  
7.  Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and 
neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86(2):104–14.  
8.  Stadler ME, Patel MR, Couch ME, Hayes DN. Molecular biology of head and neck 
cancer: risks and pathways. Hematol Oncol Clin North Am. 2008;22(6):1099–124, 
vii.  
9.  Bauer VL, Hieber L, Schaeffner Q, Weber J, Braselmann H, Huber R, et al. 
Establishment and Molecular Cytogenetic Characterization of a Cell Culture Model 
of Head and Neck Squamous Cell Carcinoma (HNSCC). Genes (Basel). 
2010;1(3):388–412.  
10.  Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization 
Classification of Tumours. Pathology & Genetics of Head and Neck Tumours. IARC 
Press; 2005.  
11.  Mastronikolis NS, Papadas TA, Goumas PD, Triantaphyllidou I-E, Theocharis DA, 
Papageorgakopoulou N, et al. Head and neck: Laryngeal tumors: an overview. Atlas 
Genet Cytogenet Oncol Haematol. 2009;13(11):888–93.  
12.  Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant 
Tumours. 7th ed. John Wiley & Sons; 2011.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 74 
 
13.  Wong T-S, Gao W, Li Z-H, Chan JY-W, Ho W-K. Epigenetic Dysregulation in 
Laryngeal Squamous Cell Carcinoma. J Oncol. 2012;2012:10 pages.  
14.  GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 
2012 (Simple Maps) . 2012 [Accessed on 2014 Dec 19]. Available from: 
http://globocan.iarc.fr/Pages/Map.aspx 
15.  GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 
2012 (Population Fact Sheets) . 2012 [Accessed on 2014 Dec 19]. Available from: 
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 
16.  Clínica Universitária ORL da Faculdade de Medicina da Universidade de Lisboa. Dia 
Mundial da Voz . 2014 [Accessed on 2014 Aug 25]. Available from: 
http://www.diamundialdavoz.com/site_dmv/cancro.asp 
17.  Cancer Research UK. Laryngeal cancer risk factors . 2014 [Accessed on 2014 Dec 
20]. Available from: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/larynx/Laryngealcancerriskfactors/ 
18.  Altieri A, Garavello W, Bosetti C, Gallus S, La Vecchia C. Alcohol consumption and 
risk of laryngeal cancer. Oral Oncol. 2005;41(10):956–65.  
19.  Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. Human papillomavirus infection and 
laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis. 
2013;207(3):479–88.  
20.  Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical 
interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11(7):512–
22.  
21.  Torrente MC, Rodrigo JP, Haigentz Jr. M, Dikkers FG, Rinaldo A, Takes RP, et al. 
Human papillomavirus infections in laryngeal cancer. Head Neck. 2011;33(4):581–6.  
22.  ViralZone. Papillomaviridae . [Accessed on 2014 Dec 22]. Available from: 
http://viralzone.expasy.org/viralzone/all_by_species/5.html 
23.  Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck 
cancer. Nat Rev Cancer. 2011;11(1):9–22.  
24.  Almadori G, Bussu F, Cadoni G, Galli J, Rigante M, Artuso A, et al. Multistep 
laryngeal carcinogenesis helps our understanding of the field cancerisation 
phenomenon: a review. Eur J Cancer. 2004;40(16):2383–8.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 75 
 
25.  MJ R. How many mutations are required for tumorigenesis? Implications from human 
cancer data. Mol Carcinog. 1993;7(3):139–46.  
26.  Sasiadek MM, Stembalska-Kozlowska A, Smigiel R, Ramsey D, Kayademir T, Blin 
N. Impairment of MLH1 and CDKN2A in oncogenesis of laryngeal cancer. Br J 
Cancer. 2004;90(8):1594–9.  
27.  Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 
2008;359(11):1143–54.  
28.  Yoo WJ, Cho SH, Lee YS, Park GS, Kim MS, Kim BK, et al. Loss of heterozygosity 
on chromosomes 3p,8p,9p and 17p in the progression of squamous cell carcinoma of 
the larynx. J Korean Med Sci. 2004;19(3):345–51.  
29.  Todorova TA, Jordanov SH, Stancheva GS, Chalakov IJ, Melnicharov MB, Kunev K 
V, et al. Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell 
Carcinoma. Pathol Oncol Res. 2015;21(2):413–21.  
30.  Stephen JK, Chen KM, Shah V, Havard S, Kapke A, Lu M, et al. DNA 
hypermethylation markers of poor outcome in laryngeal cancer. Clin Epigenetics. 
2010;1(1-2):61–9.  
31.  Marcos CA, Alonso-Guervos M, Prado NR, Gimeno TS, Iglesias FD, Hermsen M, et 
al. Genetic model of transformation and neoplastic progression in laryngeal 
epithelium. Head Neck. 2011;33(2):216–24.  
32.  Jarvinen AK, Autio R, Haapa-Paananen S, Wolf M, Saarela M, Grenman R, et al. 
Identification of target genes in laryngeal squamous cell carcinoma by high-resolution 
copy number and gene expression microarray analyses. Oncogene. 
2006;25(52):6997–7008.  
33.  Jin C, Jin Y. Head and neck: Laryngeal squamous cell carcinoma. Atlas Genet 
Cytogenet Oncol Haematol. 2007;11(1):42–5.  
34.  Keser I, Toraman AD, Ozbilim G, Guney K, Luleci G. DNA gains and losses of 
chromosome in laryngeal squamous cell carcinoma using comparative genomic 
hybridization. Yonsei Med J. 2008;49(6):949–54.  
35.  Kitamura K, Hayashi K, Kobayashi R, Ishii H, Matsubayashi J, Matsumoto T, et al. 
Clinicopathological significance of the fragile histidine triad transcription protein 
expression in laryngeal carcinogenesis. Oncol Rep. 2008;19(4):847–52.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 76 
 
36.  Lai ZL, Tsou YA, Fan SR, Tsai MH, Chen HL, Chang NW, et al. Methylation-
associated gene silencing of RARB in areca carcinogens induced mouse oral 
squamous cell carcinoma. Biomed Res Int. 2014;2014:378358.  
37.  Zou CP, Youssef EM, Zou CC, Carey TE, Lotan R. Differential effects of 
chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta 
and on retinoid resistance in human squamous carcinoma cells. Oncogene. 
2001;20(47):6820–7.  
38.  Galera-Ruiz H, Rios-Moreno MJ, Gonzalez-Campora R, Ortega I, Fernandez A, 
Garcia-Escudero A, et al. The cadherin-catenin complex in laryngeal squamous cell 
carcinoma. Eur Arch Oto-Rhino-Laryngology. 2012;269(4):1183–8.  
39.  Goulioumis AK, Varakis J, Goumas P, Papadaki H. Differential beta-catenin 
expression between glottic and supraglottic laryngeal carcinoma. Eur Arch Oto-
Rhino-Laryngology. 2010;267(10):1573–8.  
40.  Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and 
ageing. Mech Ageing Dev. 2008;129(7-8):391–407.  
41.  Sasiadek MM, Smigiel R, Stembalska A, Ramsey D, Blin N. Cyclin D1 and MLH1 
levels in laryngeal cancer are linked to chromosomal imbalance. Anticancer Res. 
2006;26(6B):4597–601.  
42.  Liu Y, Dong XL, Tian C, Liu HG. Human telomerase RNA component (hTERC) gene 
amplification detected by FISH in precancerous lesions and carcinoma of the larynx. 
Diagn Pathol. 2012;7:34.  
43.  Hermsen M, Guervos MA, Meijer G, Baak J, van Diest P, Marcos CA, et al. New 
chromosomal regions with high-level amplifications in squamous cell carcinomas of 
the larynx and pharynx, identified by comparative genomic hybridization. J Pathol. 
2001;194(2):177–82.  
44.  Van Dyke DL. Squamous cell cancer. Atlas Genet Cytogenet Oncol Hematol. 
2002;6(1):43–6.  
45.  Dionysopoulos D, Pavlakis K, Kotoula V, Fountzilas E, Markou K, Karasmanis I, et 
al. Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in 
localized laryngeal squamous cell carcinoma. Strahlentherapie und Onkol. 
2013;189(3):202–14.  
46.  Braut T, Krstulja M, Kujundzic M, Manestar D, Hadzisejdic I, Jonjic N, et al. 
Epidermal growth factor receptor protein expression and gene amplification in 
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 77 
 
normal, hyperplastic, and cancerous glottic tissue: immunohistochemical and 
fluorescent in situ hybridization study on tissue microarrays. Croat Med J. 
2009;50(4):370–9.  
47.  Liu Y, Gong LP, Dong XL, Liu HG. Detection of C-MYC oncogene translocation 
and copy number change in the normal-dysplasia-carcinoma sequence of the larynx 
by fluorescence in situ hybridization. Diagn Cytopathol. 2013;41(6):515–9.  
48.  Coskunpinar E, Oltulu YM, Orhan KS, Tiryakioglu NO, Kanliada D, Akbas F. 
Identification of a differential expression signature associated with tumorigenesis and 
metastasis of laryngeal carcinoma. Gene. 2014;534(2):183–8.  
49.  Kiwerska K, Rydzanicz M, Kram A, Pastok M, Antkowiak A, Domagala W, et al. 
Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients. Mol 
Biol Rep. 2010;37(1):325–32.  
50.  Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen 
ML, et al. Amplicon mapping and expression profiling identify the Fas-associated 
death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal 
cancer. Clin Cancer Res. 2007;13(21):6257–66.  
51.  Jarmuz-Szymczak M, Pelinska K, Kostrzewska-Poczekaj M, Bembnista E, Giefing 
M, Brauze D, et al. Heterogeneity of 11q13 region rearrangements in laryngeal 
squamous cell carcinoma analyzed by microarray platforms and fluorescence in situ 
hybridization. Mol Biol Rep. 2013;40(7):4161–71.  
52.  Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, et al. A consistent 
pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a 
breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosom 
Cancer. 2000;28(2):153–63.  
53.  Ciullo M, Debily M-A, Rozier L, Autiero M, Billault A, Mayau V, et al. Initiation of 
the breakage-fusion-bridge mechanism through common fragile site activation in 
human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. 
Hum Mol Genet. 2002;11(23):2887–94.  
54.  Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK. Cyclin D1 
overexpression and p53 inactivation immortalize primary oral keratinocytes by a 
telomerase-independent mechanism. J Clin Invest. 2001;108(5):725–32.  
55.  Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, et al. Short 
term cyclin D1 overexpression induces centrosome amplification, mitotic spindle 
abnormalities, and aneuploidy. J Biol Chem. 2005;280(1):768–76.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 78 
 
56.  Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. 
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is 
associated with enhanced cell proliferation and resistance to the epidermal growth 
factor receptor inhibitor gefitinib. Cancer Res. 2007;67(19):9304–14.  
57.  Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ. Cortactin overexpression 
inhibits ligand-induced down-regulation of the epidermal growth factor receptor. 
Cancer Res. 2005;65(8):3273–80.  
58.  Van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by 
regulating intercellular adhesion and cell spreading. Exp Cell Res. 2006;312(9):1658–
70.  
59.  Gibcus JH, Mastik MF, Menkema L, de Bock GH, Kluin PM, Schuuring E, et al. 
Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer. 
2008;98(5):950–5.  
60.  Gibcus JH. Characterization of the 11q13.3 amplicon in head and neck squamous cell 
carcinoma. The Department of Pathology and Laboratory Medicine. University of 
Groningen; 2008.  
61.  Stembalska A, Blin N, Ramsey D, Sasiadek MM. Three distinct regions of deletion 
on 13q in squamous cell carcinoma of the larynx. Oncol Rep. 2006;16(2):417–21.  
62.  Schlade-Bartusiak K, Stembalska A, Ramsey D. Significant involvement of 
chromosome 13q deletions in progression of larynx cancer, detected by comparative 
genomic hybridization. J Appl Genet . 2005/11/10 ed. 2005;46(4):407–13. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/16278516 
63.  Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of 
epigenetics. Genes Dev. 2009;23(7):781–3.  
64.  Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: 
prospects and challenges. Trends Genet. 2014;30(2):75–84.  
65.  Varela-Rey M, Woodhoo A, Martinez-Chantar ML, Mato JM, Lu SC. Alcohol, DNA 
methylation, and cancer. Alcohol Res Curr Rev. 2013;35(1):25–35.  
66.  Ovcharenko I, Loots GG, Nobrega MA, Hardison RC, Miller W, Stubbs L. Evolution 
and functional classification of vertebrate gene deserts. Genome Res. 
2005;15(1):137–45.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 79 
 
67.  Lopez F, Sampedro T, Llorente JL, Dominguez F, Hermsen M, Suarez C, et al. Utility 
of MS-MLPA in DNA methylation profiling in primary laryngeal squamous cell 
carcinoma. Oral Oncol. 2014;50(4):291–7.  
68.  Pierini S, Jordanov SH, Mitkova A V, Chalakov IJ, Melnicharov MB, Kunev K V, et 
al. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in 
laryngeal squamous cell carcinoma and their associations with clinical profiles of the 
patients. Head Neck. 2014;36(8):1103–8.  
69.  Starska K, Forma E, Lewy-Trenda I, Papiez P, Wos J, Brys M. Diagnostic impact of 
promoter methylation and E-cadherin gene and protein expression levels in laryngeal 
carcinoma. Contemp Oncol. 2013;17(3):263–71.  
70.  Smigiel R, Sasiadek M, Krecicki T, Ramsey D, Jagielski J, Blin N. Inactivation of the 
cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma 
of the larynx. Mol Carcinog . 2004/03/03 ed. 2004;39(3):147–54. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14991744 
71.  Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, et 
al. Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients 
with laryngeal and hypopharyngeal cancers. Cancer. 2007;110(8):1745–51.  
72.  Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN. The involvement of CHD5 
hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol. 
2011;47(7):601–8.  
73.  Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W. Frequent 
hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal 
squamous cell carcinomas and adjacent normal mucosa. Oral Oncol. 2011;47(2):104–
7.  
74.  Kong WJ, Zhang S, Guo C, Wang Y, Zhang D. Methylation-associated silencing of 
death-associated protein kinase gene in laryngeal squamous cell cancer. 
Laryngoscope. 2005;115(8):1395–401.  
75.  Park SY, Kim BH, Kim JH, Cho NY, Choi M, Yu EJ, et al. Methylation profiles of 
CpG island loci in major types of human cancers. J Korean Med Sci. 2007;22(2):311–
7.  
76.  Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 
2014;4(2):89–115.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 80 
 
77.  Rodrigo JP, Dominguez F, Alvarez C, Manrique C, Herrero A, Suarez C. Expression 
of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations 
to clinicopathological features. Eur J Cancer. 2002;38(8):1059–64.  
78.  Rodrigo JP, Dominguez F, Suarez V, Canel M, Secades P, Chiara MD. Focal adhesion 
kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Arch 
Otolaryngol Neck Surg. 2007;133(2):145–50.  
79.  Liu J, Guo Y, Fu S, Yang M, Sun KL, Fu WN. Hypomethylation-induced expression 
of S100A4 increases the invasiveness of laryngeal squamous cell carcinoma. Oncol 
Rep. 2010;23(4):1101–7.  
80.  Jiao J, Qin Z, Li S, Liu H, Lu Z. Potential role of Notch1 signaling pathway in 
laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, 
cell cycle arrest, cell apoptosis, and cell migration. Oncol Rep. 2009;22(4):815–23.  
81.  Lionello M, Lovato A, Staffieri A, Blandamura S, Turato C, Giacomelli L, et al. The 
EGFR-mTOR pathway and laryngeal cancer angiogenesis. Eur Arch Oto-Rhino-
Laryngology. 2014;271(4):757–64.  
82.  Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? 
Nat Rev Cancer. 2003;3(10):756–67.  
83.  Burtness B, Golemis EA. Molecular Determinants of Head and Neck Cancer. 
Springer; 2014.  
84.  Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent 
mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. 
Cancer Discov. 2013;3(7):761–9.  
85.  Zhang H, Zhang D, Luan X, Xie G, Pan X. Inhibition of the signal transducers and 
activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal 
carcinoma cells. J Int Med Res. 2010;38(5):1673–81.  
86.  Flowers LO. Targeting JAK-STAT signal transduction pathways in human 
carcinomas. Int J Biosci. 2013;3(8):241–50.  
87.  Gao LF, Xu DQ, Wen LJ, Zhang XY, Shao YT, Zhao XJ. Inhibition of STAT3 
expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer 
cells. Acta Pharmacol Sin. 2005;26(3):377–83.  
88.  Coleman WB, Tsongalis GJ. Molecular Diagnostics for the Clinical Laboratorian. 2nd 
ed. Humana Press; 2006.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 81 
 
89.  Theisen A. Microarray-based comparative genomic hybridization (aCGH). Nat Educ. 
2008;1(1):45.  
90.  Nussbaum RL, Mcinnes RR, Willard HF. Thompson & Thompson - Genética Médica 
. 7th ed. Elsevier; 2008.  
91.  Shinawi M, Cheung SW. The array CGH and its clinical applications. Drug Discov 
Today. 2008;13(17-18):760–70.  
92.  Bejjani BA, Shaffer LG. Application of array-based comparative genomic 
hybridization to clinical diagnostics. J Mol Diagnostics. 2006;8(5):528–33.  
93.  Stuppia L, Antonucci I, Palka G, Gatta V. Use of the MLPA Assay in the Molecular 
Diagnosis of Gene Copy Number Alterations in Human Genetic Diseases. Int J Mol 
Sci. 2012;13(3):3245–76.  
94.  Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative 
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe 
amplification. Nucleic Acids Res. 2002;30(12 e57).  
95.  MRC-Holland. MLPA protocol for the detection and quantification of nucleic acid 
sequences - MLPA DNA Protocol version MDP-005 . 2014 [Accessed on 2015 Jan 
9]. Available from: http://mlpa.com/WebForms/WebFormMain.aspx?Tag=_wl2zCji-
rCGANQgZPuTixtCplCA1mmwJoFo_xHPnTgc. 
96.  MRC-Holland. Interpretation of MLPA results - Description version 02 . 2010 
[Accessed on 2015 Jan 9]. Available from: 
http://mlpa.com/WebForms/WebFormMain.aspx?Tag=_wl2zCji-
rCGANQgZPuTixrMkcAVlTxSUI1uxaJsuta9GGaLIE8p67Q.. 
97.  MRC-Holland. MLPA® - an introduction . 2015 [Accessed on 2015 Jan 9]. Available 
from: http://www.mlpa.com/WebForms/WebFormMain.aspx?Tag=_wl2zCji-
rCGANQgZPuTixsEyIW1MscfzuKj2NDFYc-g. 
98.  MRC-Holland. General MS-MLPA protocol for the detection and quantification of 
nucleic acid sequences and methylation profiling. - MS-MLPA protocol version 
MSP-v004 . 2013 [Accessed on 2015 Jan 9]. Available from: 
http://mlpa.com/WebForms/WebFormMain.aspx?Tag=_wl2zCji-rCGANQgZPu 
99.  Roche. High Pure PCR Template Preparation Kit . 2008 [Accessed on 2015 Feb 2]. 
Available from: 
http://lifescience.roche.com/wcsstore/RASCatalogAssetStore/Articles/05204933001
_03.08.pdf 
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 82 
 
100.  Thermo Fisher Scientific. NanoDrop 1000 Spectrophotometer | V3.7 User’s Manual 
. 2008 [Accessed on 2015 Feb 2]. Available from: 
http://www.nanodrop.com/library/nd-1000-v3.7-users-manual-8.5x11.pdf 
101.  Agilent Tecnhologies. Agilent Oligonucleotide Array-Based CGH for Genomic DNA 
Analysis - Enzymatic Labeling for Blood, Cells, or Tissues (with a High Throughput 
option) - Protocol Version 7.3 March 2014. . 2014 [Accessed on 2015 Jan 2]. 
Available from: http://www.chem.agilent.com/Library/usermanuals/Public/G4410-
90010_CGH_Enzymatic_7.3.pdf 
102.  Takebayashi S, Hickson A, Ogawa T, Jung KY, Mineta H, Ueda Y, et al. Loss of 
chromosome arm 18q with tumor progression in head and neck squamous cancer. 
Genes Chromosom Cancer. 2004;41(2):145–54.  
103.  Golam Sabbir M, Roy A, Mandal S, Dam A, Roychoudhury S, Panda CK. Deletion 
mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian 
patients: Correlation with prognosis of the tumour. Int J Exp Pathol. 2006;87(2):151–
61.  
104.  Parikh RA, White JS, Huang X, Schoppy DW, Baysal BE, Baskaran R, et al. Loss of 
distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing 
radiation in head and neck squamous cell carcinoma. Genes Chromosom Cancer. 
2007;46(8):761–75.  
105.  Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, Sunwoo JB, et al. Transcript 
map of the 8p23 putative tumor suppressor region. Genomics. 2001;75(1-3):17–25.  
106.  Lin L, Aggarwal S, Glover TW, Orringer MB, Hanash S, Beer DG. A minimal critical 
region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using 
sequence tagged site-amplification mapping and quantitative polymerase chain 
reaction includes the GATA-4 gene. Cancer Res. 2000;60(5):1341–7.  
107.  Ye H, Pungpravat N, Huang BL, Muzio LL, Mariggiò MA, Chen Z, et al. Genomic 
assessments of the frequent loss of heterozygosity region on 8p21.3∼p22 in head and 
neck squamous cell carcinoma. Cancer Genet Cytogenet. 2007;176(2):100–6.  
108.  Sheu JJ-C, Hua C-H, Wan L, Lin Y-J, Lai M-T, Tseng H-C, et al. Functional genomic 
analysis identified epidermal growth factor receptor activation as the most common 
genetic event in oral squamous cell carcinoma. Cancer Res. 2009;69(6):2568–76.  
109.  Ashman JNE, Patmore HS, Condon LT, Cawkwell L, Stafford ND, Greenman J. 
Prognostic value of genomic alterations in head and neck squamous cell carcinoma 
detected by comparative genomic hybridisation. Br J Cancer. 2003;89(5):864–9.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 83 
 
110.  Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, et al. p63 
overexpression associates with poor prognosis in head and neck squamous cell 
carcinoma. Hum Pathol. 2005;36(2):187–94.  
111.  Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, et al. Genomic 
gain of PIK3CA and increased expression of p110alpha are associated with 
progression of dysplasia into invasive squamous cell carcinoma. J Pathol. 
2002;198(3):335–42.  
112.  González M V, Pello MF, Ablanedo P, Suárez C, Alvarez V, Coto E. Chromosome 
3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in 
squamous cell carcinoma of the head and neck. J Clin Pathol. 1998;51(7):520–4.  
113.  Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, et al. 
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour 
suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur 
J Cancer. 2002;38(12):1585–92.  
114.  Henken FE, Wilting SM, Overmeer RM, van Rietschoten JGI, Nygren AOH, Errami 
A, et al. Sequential gene promoter methylation during HPV-induced cervical 
carcinogenesis. Br J Cancer. 2007 Nov 19;97(10):1457–64.  
115.  Buyru N, Altinisik J, Ozdemir F, Demokan S, Dalay N. Methylation Profiles in Breast 
Cancer. Cancer Invest. 2009 Jan;27(3):307–12.  
116.  Janssen JJWM, Denkers F, Valk P, Cornelissen JJ, Schuurhuis G-J, Ossenkoppele GJ. 
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells. 
Haematologica. 2010 Jun 1;95(6):1036–7.  
117.  Marzese DM, Gago FE, Orozco JI, Tello OM, Roqué M, Vargas-Roig LM. Aberrant 
DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. 
J Med Case Rep. 2011;5(1):516.  
118.  Schwarzenbach H, Chun FK-H, Isbarn H, Huland H, Pantel K. Genomic profiling of 
cell-free DNA in blood and bone marrow of prostate cancer patients. J Cancer Res 
Clin Oncol. 2011 May;137(5):811–9.  
119.  Joosse SA, Brandwijk KIM, Devilee P, Wesseling J, Hogervorst FBL, Verhoef S, et 
al. Prediction of BRCA2-association in hereditary breast carcinomas using array-
CGH. Breast Cancer Res Treat. 2012 Apr;132(2):379–89.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 84 
 
120.  MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The Database of Genomic 
Variants: A curated collection of structural variation in the human genome. Nucleic 
Acids Res. 2014;42(D1).  
121.  Gollin SM. Cytogenetic Alterations and their Molecular Genetic Correlates in Head 
and Neck Squamous Cell Carcinoma: A Next Generation Window to the Biology of 
Disease. Genes Chromosomes Cancer. 2014;53(12):972–90.  
122.  Álvarez-Marcos C, López F, Alonso-Guervós M, Domínguez F, Suárez C, Hermsen 
MA, et al. Genetic and protein markers related to laryngeal epithelial precursor lesions 
and their neoplastic progression. Acta Otolaryngol. 2012;133(3):281–90.  
123.  Zhang S, Zhou X, Wang B, Zhang K, Liu S, Yue K, et al. Loss of VHL expression 
contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma. 
Oral Oncol. 2014;50(9):809–17.  
124.  Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev 
Cancer. 2008;8(9):705–13.  
125.  Lee DJ, Schönleben F, Banuchi VE, Qiu W, Close LG, Assaad AM, et al. Multiple 
tumor-suppressor genes on chromosome 3p contribute to head and neck squamous 
cell carcinoma tumorigenesis. Cancer Biol Ther. 2010;10(7):689–93.  
126.  Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, et al. Gene 
dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis 
and chemoradioresistance of cervical cancer. PLoS Genet. 2009;5(11).  
127.  Uchida K, Oga A, Nakao M, Mano T, Mihara M, Kawauchi S, et al. Loss of 3p26.3 
is an independent prognostic factor in patients with oral squamous cell carcinoma. 
Oncol Rep. 2011;26(2):463–9.  
128.  He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF, et al. CHL1 is involved in human 
breast tumorigenesis and progression. Biochem Biophys Res Commun. 
2013;438(2):433–8.  
129.  Redon R, Hussenet T, Bour G, Caulee K, Jost B, Muller D, et al. Amplicon mapping 
and transcriptional analysis pinpoint Cyclin L as a candidate oncogene in head and 
neck cancer. Cancer Res. 2002;62(21):6211–7.  
130.  Vander Broek R, Mohan S, Eytan D, Chen Z, Van Waes C. The PI3K/Akt/mTOR 
axis in head and neck cancer: Functions, aberrations, cross-talk, and therapies. Oral 
Diseases. 2013;  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 85 
 
131.  Ribeiro IP, Marques F, Caramelo F, Ferrão J, Prazeres H, Julião MJ, et al. Genetic 
imbalances detected by multiplex ligation-dependent probe amplification in a cohort 
of patients with oral squamous cell carcinoma-the first step towards clinical 
personalized medicine. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 
2014;35:4687–95.  
132.  Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 Is an 
Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell 
Carcinomas. Nat Genet. 2009;41(11):1238–42.  
133.  Sarkaria I, O-Charoenrat P, Talbot SG, Reddy PG, Ngai I, Maghami E, et al. 
Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and 
activated by amplification in squamous cell carcinomas. Cancer Res. 
2006;66(19):9437–44.  
134.  Kanao H, Enomoto T, Kimura T, Fujita M, Nakashima R, Ueda Y, et al. 
Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine 
cervical cancer. Cancer Res. 2005;65(19):8640–5.  
135.  Nagelkerke A, Mujcic H, Bussink J, Wouters BG, Van Laarhoven HWM, Sweep 
FCGJ, et al. Hypoxic regulation and prognostic value of LAMP3 expression in breast 
cancer. Cancer. 2011;117(16):3670–81.  
136.  Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, et al. Frequent 
overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-
27 in squamous cell carcinoma of the lung. Int J Cancer. 2007;120(12):2538–44.  
137.  Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, et al. Over-expression of eukaryotic 
translation initiation factor 4 gamma 1 correlates with tumor progression and poor 
prognosis in nasopharyngeal carcinoma. Mol Cancer. 2010;9:78.  
138.  Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, et al. Identification 
of genes associated with tumorigenesis and metastatic potential of hypopharyngeal 
cancer by microarray analysis. Oncogene. 2004;23(14):2484–98.  
139.  Hamada T, Wakamatsu T, Miyahara M, Nagata S, Nomura M, Kamikawa Y, et al. 
MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer. 
2012;130(8):1768–76.  
140.  Xiao X, Wang L, Wei P, Chi Y, Li D, Wang Q, et al. Role of MUC20 overexpression 
as a predictor of recurrence and poor outcome in colorectal cancer. J Transl Med. 
2013;11(1):151.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 86 
 
141.  Chen CH, Wang SW, Chen CW, Huang MR, Hung JS, Huang HC, et al. MUC20 
overexpression predicts poor prognosis and enhances EGF-induced malignant 
phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer. 
Gynecol Oncol. 2013;128(3):560–7.  
142.  Mahajan K, Mahajan NP. ACK1 tyrosine kinase: Targeted inhibition to block cancer 
cell proliferation. Cancer Letters. 2013. p. 185–92.  
143.  Sticht C, Hofele C, Flechtenmacher C, Bosch FX, Freier K, Lichter P, et al. 
Amplification of Cyclin L1 is associated with lymph node metastases in head and 
neck squamous cell carcinoma (HNSCC). Br J Cancer. 2005;92(4):770–4.  
144.  Orzol P, Holcakova J, Nekulova M, Nenutil1 R, Vojtesek B, Coates PJ. The diverse 
oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer 
site. Histol Histopathol. 2014;30.  
145.  Rodrigo JP, Álvarez-Alija G, Menéndez ST, Mancebo G, Allonca E, García-
Carracedo D, et al. Cortactin and focal adhesion kinase as predictors of cancer risk in 
patients with laryngeal premalignancy. Cancer Prev Res. 2011;4(8):1333–41.  
146.  Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, et al. Frequent 
Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote 
Malignant Pleural Mesothelioma. J Thorac Oncol. 2014;9(7):998–1007.  
147.  Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. 
Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in 
colorectal cancers. Br J Cancer. 2014;110(1):164–71.  
148.  Li M, Xiao LT, Yao H, Lu J, Ge J, Guo Y, et al. ASAP1 mediates the invasive 
phenotype of human laryngeal squamous cell carcinoma to affect survival prognosis. 
Oncol Rep. 2014;31(6):2676–82.  
149.  Chuang J-Y, Chang A-C, Chiang I-P, Tsai M-H, Tang C-H. Apoptosis Signal-
Regulating Kinase 1 Is Involved in WISP-1-Promoted Cell Motility in Human Oral 
Squamous Cell Carcinoma Cells. PLoS One. 2013;8(10):e78022.  
150.  Hellebrekers DMEI, Lentjes MHFM, Van Den Bosch SM, Melotte V, Wouters KAD, 
Daenen KLJ, et al. GATA4 and GATA5 are potential tumor suppressors and 
biomarkers in colorectal cancer. Clin Cancer Res. 2009;15(12):3990–7.  
151.  Swellam M, El-Arab LRE, Adly A. Prognostic value of cell-cycle regulators and 
cellular biomarkers in laryngeal squamous cell carcinoma. Clin Biochem. 
2008;41(13):1059–66.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 87 
 
152.  Ruiz C, Martins JR, Rudin F, Schneider S, Dietsche T, Fischer CA, et al. Enhanced 
expression of ANO1 in head and neck squamous cell carcinoma causes cell migration 
and correlates with poor prognosis. PLoS One. 2012;7(8).  
153.  Ayoub C, Wasylyk C, Li Y, Thomas E, Marisa L, Robé A, et al. ANO1 amplification 
and expression in HNSCC with a high propensity for future distant metastasis and its 
functions in HNSCC cell lines. Br J Cancer. 2010;103(5):715–26.  
154.  Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, et al. 
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer 
progression. Cancer Res. 2012;72(13):3270–81.  
155.  Tan KD, Zhu Y, Hiang KT, Rajasegaran V, Aggarwal A, Wu J, et al. Amplification 
and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head 
and neck squamous cell carcinoma. Genes Chromosom Cancer. 2008;47(4):353–62.  
156.  Lu B, Di W, Wang H, Ma H, Li J, Zhang Q. Tumor suppressor TSLC1 is implicated 
in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by 
regulating Akt signaling pathway. Tumor Biology. 2012;1–11.  
157.  Rivera J, Megías D, Bravo J. Sorting nexin 6 interacts with breast cancer metastasis 
suppressor-1 and promotes transcriptional repression. J Cell Biochem. 
2010;111(6):1464–72.  
158.  Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck 
cancer--an update of recent developments-. Head Neck Oncol. 2010;2:8.  
159.  Taguchi A, Taylor AD, Rodriguez J, Celikta M, Liu H, Ma X, et al. A Search for 
Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding 
the Repertoire of Potential Immunotherapeutic Targets. Cancer Res. 
2014;74(17):4694–705.  
160.  Li F-Y, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMEN 
disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity 
against Epstein-Barr virus. Blood. 2014;123(14):2148–52.  
161.  Chaigne-Delalande B, Li F-Y, O’Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. 
Mg2+ Regulates Cytotoxic Functions of NK and CD8 T Cells in Chronic EBV 
Infection Through NKG2D. Science (80- ). 2013 Jul 12;341(6142):186–91.  
162.  Silva Veiga LC, Bérgamo NA, Reis PP, Kowalski LP, Rogatto SR. Loss of Y-
chromosome does not correlate with age at onset of head and neck carcinoma: A case-
control study. Brazilian J Med Biol Res. 2012;45(2):172–8.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 88 
 
163.  Kujawski M, Jarmuz M, Rydzanicz M, Szukala K, Wierzbicka M, Grenman R, et al. 
Frequent chromosome Y loss in primary, second primary and metastatic squamous 
cell carcinomas of the head and neck region. Cancer Lett. 2004;208(1):95–101.  
164.  Edlund K, Lindskog C, Saito A, Berglund A, Pontén F, Göransson-Kultima H, et al. 
CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer. 
2012;131(10):2264–73.  
165.  Jung HL, Kim SH, Wang LH, Choi Y La, Young CK, Jin HK, et al. Clinical 
significance of CD99 down-regulation in gastric adenocarcinoma. Clin Cancer Res. 
2007;13(9):2584–91.  
166.  Xu F, Zhou G, Han S, Yuan W, Chen S, Fu Z, et al. Association of TNF-α, 
TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast 
Cancer in Northeast Chinese Han Women. PLoS One. 2014;9(7):e101138.  
167.  Castillo A, Paul A, Sun B, Huang TH, Wang Y, Yazinski SA, et al. The BRCA1-
Interacting Protein Abraxas Is Required for Genomic Stability and Tumor 
Suppression. Cell Reports. 2014;  
168.  López F, Álvarez-Marcos C, Alonso-Guervós M, Domínguez F, Suárez C, Hermsen 
MA, et al. From laryngeal epithelial precursor lesions to squamous carcinoma of the 
larynx: the role of cell cycle proteins and β-catenin. Eur Arch Oto-Rhino-
Laryngology. 2013;270(12):3153–62.  
169.  Bodnar M, Szylberg Ł, Kaźmierczak W, Marszałek A. Immunohistochemical 
expression of p27kip1 in metastatic laryngeal squamous cell carcinoma. Adv Med 
Sci. 2014;59(2):206–12.  
170.  Bai YX, Yi JL, Li JF, Sui H. Clinicopathologic significance of BAG1 and TIMP3 
expression in colon carcinoma. World J Gastroenterol. 2007;13(28):3883–5.  
171.  Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, Pagliardini S, et al. TIMP3 
regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. 
Oncogene. 2011;30(27):3011–23.  
172.  Verschuur-Maes AHJ, De Bruin PC, Van Diest PJ. Epigenetic progression of 
columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res Treat. 
2012;136(3):705–15.  
173.  Moelans CB, Verschuur-Maes AHJ, Van Diest PJ. Frequent promoter 
hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal 
carcinoma in situ and invasive breast cancer. J Pathol. 2011;225(2):222–31.  
Genetic and Epigenetic Characterization of Laryngeal Carcinoma 
  
Vanessa Marques 89 
 
174.  Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor 
suppressor genes in ovarian cancer. Exp Ther Med. 2012;4(6):1092–6.  
175.  Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J. Promoter 
methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and 
neck squamous cell carcinoma: Pharmacological genome demethylation reduces 
proliferation of head and neck squamous carcinoma cells. Oncol Rep. 
2012;27(4):1135–41.  
176.  Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, et al. 
Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation 
correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol 
Ther. 2009;8(5):444–51.  
177.  Neill NJ, Torchia BS, Bejjani BA, Shaffer LG, Ballif BC. Comparative analysis of 
copy number detection by whole-genome BAC and oligonucleotide array CGH. Mol 
Cytogenet. 2010;3:11.  
178.  Kloosterman WP, Koster J, Molenaar JJ. Prevalence and clinical implications of 
chromothripsis in cancer genomes. Curr Opin Oncol. 2014;26(1):64–72.  
179.  Forment J V., Kaidi A, Jackson SP. Chromothripsis and cancer: causes and 
consequences of chromosome shattering. Nature Reviews Cancer. 2012. 12(10):663-
70  
180.  Willis AS, van den Veyver I, Eng CM. Multiplex ligation-dependent probe 
amplification (MLPA) and prenatal diagnosis. Prenatatal Diagnosis. 2012;32(4):315–
20.  
181.  MRC-Holland. Methylation-specific MLPA® (MS-MLPA) . 2015 [Accessed on 
2015 Jan 9]. Available from: 
https://mlpa.com/WebForms/WebFormMain.aspx?Tag=_zjCZBtdOUyAt3KF3EwR
ZhMUCJLqQzwZq_fiQWQTnAP-0V13AZUzpnKmyAPu7IsFt  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
i 
 
 
 
 
 
 
 
 
APPENDICES 
  
  
  
 
 
  
  
iii 
 
Appendices I - Abstract regarding oral presentation in VIII Conferences of Genetic and 
Biotechnology 
Detection of Chromosomal Alterations in Laryngeal Squamous Cell 
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Introduction:  
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignant tumour in 
the world and it can arise from ten anatomic sites. Among them, the larynx is the second most 
common affected organ. It is generally accepted that solid tumours, such as laryngeal squamous cell 
carcinoma (LSCC), results from a multistep process in which genetic alterations are accumulated. 
However, since genetic alterations in LSCC are usually studied as part of head and neck cancers, 
there is not much information about molecular progression that allow a clear differentiation between 
laryngeal malignancies and the other types of cancer included in head and neck family. 
In most cases, laryngeal carcinoma have origin on the vocal cords in the glottic region or in 
supraglottic region, thus affecting vital functions such as breathing, swallowing and speaking. Taking 
this into consideration, the optimal management of patients diagnosed with laryngeal carcinoma is 
critical. Also, 5-year survival rate has not improved in more than two decades. One of the main 
challenges is to identify specific tumour markers that will help to improve survival rates and preserve 
the function of the larynx.  
Material and Methods:  
DNA was extracted from eight fresh-frozen tissue samples of laryngeal tumors, collected from 
patients with LSCC, after surgery. Copy number variations were accessed by Array Comparative 
Genomic Hybridization and one sample from palatine uvula was used as control.  
Results:  
The results showed several structural rearrangements which were most frequently located in the 
chromosomes 3, 8, 9, 11 and Y. Among this alterations, the most common imbalances were loss of 
chromosomal regions 3p, 8p, 9p, Yp and Yq while the most common gains were located in 3q, 8p, 
8q and 11q. Smaller alterations were also found, being the gain in 14q13.1 one of the most frequent 
ones.  
Conclusion:  
Our study revealed several chromosomal alterations that may be implied in the development of 
laryngeal carcinoma. The correlation between genetic alterations and clinic-pathological data has the 
power to identify putative biomarkers with possible diagnostic and prognostic value. 
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Introduction: 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignant tumour in 
the world and it can arise from the larynx. The presence of a tumour in this region leads to impairment 
of vital anatomical structures. Also, laryngeal tumours are usually diagnosed in a late stage.  
Solid tumours, such as laryngeal squamous cell carcinoma (LSCC), result from a multistep process 
where genetic alterations play a major role. However, those alterations are usually studied as part of 
HNSCC and so one of the major challenges is to identify tumour markers that will help to distinguish 
laryngeal tumours from other cancers included in head and neck family and to improve its survival 
rates. 
Material and Methods: 
DNA was extracted from eight fresh-frozen tissue samples of laryngeal tumours, collected from 
patients with LSCC, after surgery. Copy number variations (CNV) were accessed by Array 
Comparative Genomic Hybridization (aCGH) and one sample from palatine uvula was used as 
control.  
Methylation-Specific Multiplex Ligation-dependent Probe Amplification (MS-MLPA) was used to 
access CNV and to analyse the methylation profile of the same samples. For each MS-MLPA 
reaction, three different controls, which were also extracted from palatine uvula, were used.  
Results: 
aCGH results showed mainly gains of genetic material, especially on chromosome 3q, 8q, 11q and 
14q13.1. The most common losses were located on chromosomal regions 3p, 8p, 9p, 12p, Yp and 
Yq. Overall, MS-MLPA results support the alterations found by aCGH. Regarding the methylation 
profile, no genes were found to be significantly methylated.  
Conclusion: 
Although no significant epigenetic changes were found, our study revealed several chromosomal 
alterations that may be implied in molecular progression of laryngeal cancer. The correlation between 
genetic alterations and clinic-pathological data has the power to identify putative biomarkers with 
possible diagnostic and prognostic value. 
 
 
  
 
 
 
 
